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1 Introduction 
1.1 The Liver 
The liver is the biggest glandular organ in the vertebrate body and is divided into 
four lobes of unsymmetrical shape and size. Blood is carried to the liver by the 
hepatic artery and the portal vein. The hepatic artery carries oxygen-rich blood 
from the aorta. Blood from the digestive system is first filtered by the liver before it 
migrates to the rest of the body. The portal vein carries blood containing digested 
food from the small intestine. These blood vessels subdivide in the liver 
repeatedly, terminating in very small capillaries. Each capillary leads to a lobule in 
which it branches out to even smaller vessels called sinusoids. The liver is 
composed of thousands of lobules, and each lobule consists of hepatocytes, the 
parenchymal and metabolic cells of the liver (1). 
The liver has a wide range of functions. It plays a major role in metabolism 
including controlling the blood levels of lipids, amino acids and glucose. The liver 
converts carbohydrates into glucose and vice versa glucose into its storable form 
glycogen to provide persistant energy supply for the body. When the blood sugar 
level declines, glycogen is metabolized back into glucose. Moreover, the liver 
generates bile, an alkaline compound which is stored in the gall bladder and 
assists in digestion by emulsification of lipids (2). The liver decomposes ammonia, 
a toxic waste product of protein metabolism, into urea, which is then discarded via 
the urine. Furthermore, degradation of erythrocytes, plasma protein synthesis, 
hormone production, detoxification and production of biochemicals necessary for 
processing digested food are key processes taking place in the liver. It also has an 
intrinsic storage function for iron, vitamins and other essential chemicals. Besides 
fighting infections in the body by purging the blood of particles and 
microorganisms including bacteria, the liver is also a site for induction of immune-
tolerance due to its exposure to various compounds of nutrition every day (3).  
The liver is the only internal human organ capable of natural regeneration and 
mass recovery after tissue loss, since only 25% of the liver can regenerate into a 
whole liver. This regeneration process is primarily accomplished by hepatocytes 
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re-entering the cell cycle and liver resident stem cells, called hepatic oval cells, 
which can differentiate into hepatocytes (1,2). 
1.2 Liver diseases 
Liver diseases are categorized by the cause as well as the effect which they have 
on the liver. Causes may include infection, injury, exposure to drugs or toxic 
compounds, an autoimmune process or a genetic defect (4). These causes can 
lead to hepatitis, cirrhosis, fatty liver and potentially to liver cancer (5). Liver 
diseases show a great diversity of disturbances in liver function and structure with 
characteristic hallmarks often leading to different forms of hepatitis and cirrhosis 
(6). Fatty liver is the most common indication of alcohol-induced liver disorders. 
Fat accumulates inside the liver cells, causing cell enlargement (steatosis) and 
sometimes cell damage (steatohepatitis), which can lead to cirrhosis (3). Similar 
changes are also seen in people who do not drink excessive amounts of alcohol 
but are obese or have diabetes. 
Anything that causes severe ongoing injury to the liver can lead to cirrhosis. This is 
marked by cell death and scar formation and is a progressive disease that creates 
irreversible damage (7). Cirrhosis is treated only by trying to limit further damage. 
If it is caused by a virus or another treatable cause of liver injury, treating the 
cause can stabilize the disease and prevent impairment of liver functions. 
Cirrhosis has no signs or symptoms in its early stages, but as it progresses, it can 
cause ascites, muscle wasting, bleeding from the intestine, easy bruising, 
gynecomastia, and a number of other problems (8). In extreme cases, a liver 
transplantation may be needed. Since the liver is responsible for the metabolism of 
alcohol, drugs, and environmental toxins, prolonged exposure to any of these 
substances can also cause hepatitis and/or cirrhosis and have the potential to 
cause life-threatening acute liver failure. 
Hepatitis can be divided in two major forms. One, in which the liver is inflamed 
quickly called acute hepatitis, and one, in which the liver is inflamed and damaged 
slowly over a long period of time called chronic hepatitis. While hepatitis can be 
caused by any of the means mentioned above, most commonly it is due to 
infection by one of several viruses, termed hepatitis viruses (8). These viruses 
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have been named in the order of their discovery as hepatitis A, B, C, D, and E. In 
addition to the hepatitis viruses, other viruses can also cause hepatitis including 
Cytomegalovirus, Epstein-Barr Virus, and Yellow Fever Virus (8). Deviant 
presentation of human leukocyte antigen (HLA) class II on the surface of 
hepatocytes, possibly due to genetic predisposition or acute liver infection, causes 
a cell-mediated immune response against the own liver, resulting in autoimmune 
hepatitis (AIH) (9). AIH can be divided into three subtypes depending on the 
targets of expressed IgG antibodies (10). Type I is characterized by elevated 
levels of antinuclear antibody (ANA) and anti-smooth muscle actin antibody (SMA) 
in the blood. Type II shows high levels of liver/kidney microsomal antibody 
(LKM-1), whereas anti soluble liver antigen (SLA) is representative for Type III AIH 
(11). 
Another form of hepatitis is ischemic hepatitis, also known as shock liver, which is 
marked by decreased blood flow (perfusion) to the liver and is usually due to 
shock or low blood pressure. It can be caused by local problems with the blood 
vessels that supply oxygen to the liver such as thrombosis, or clotting of the 
hepatic artery which partially supplies blood to liver cells. Blood testing usually 
shows high levels of the liver transaminase enzymes, alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST), due to the damaged hepatocytes 
leaking out these enzymes into the blood steam (3). 
Although the pathogenesis of hepatic diseases remains vague, several lines of 
evidence suggest that cytokines may play a predominant role in the pathogenesis 
of hepatic diseases. It is well known that several cytokines, especially Tumor 
Necrosis Factor alpha (TNF-α), show hepatoxicity and are suggested to cause 
hepatic damage in clinical and experimental sepsis and endotoxemia (12). During 
endotoxemia, toxins that are intracellular resident and not secreted in a soluble 
form by life bacteria are released when bacteria cells are lysed. Serum levels of 
TNF-α, Interleukin-1 (IL-1) and IL-6 were elevated in patients with alcoholic 
hepatitis (13,14), suggesting an involvement of these cytokines in this liver lesion. 
With regards to viral hepatitis, it is suggested that T-cell dependent cytotoxicity 
against virus infected hepatic cells is responsible for the hepatic lesions (15). 
Cytokines, however, may also be involved in the hepatocyte injury directly or by 
activating the immune system (16), since cytokines, inluding TNF-α, IL-1, IL-2, 
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IL-4, and Interferon gamma (IFN-γ), are reported to be elevated in patients with 
chronic viral liver disease (17-19), and cells expressing Interferon alpha (IFN-α) 
and IFN-γ are localized in the liver tissue of these patients (20). 
When cancer does arise in the liver, it is called primary liver cancer (21). The most 
common type is the hepatocellular carcinoma, which means cancer that develops 
in the liver’s hepatocyte cells. Hepatitis and cirrhosis are the predominant risk 
factors to develop hepatocellular carcinoma (22). In some cases cancer starts in 
other parts of the body and then metastasizes (spreads) to the liver called 
metastatic liver cancer (23). 
1.3 Liver as an immune organ 
Structurally and functionally qualification of the liver as a lymphoid organ has been 
implied in several studies (24-26). The liver can be considered as an immune 
organ because it hosts the largest population of tissue resident macrophages 
named Kupffer cells (KCs) in the body and different types of dendritic cells (DCs), 
and it is also uniquely enriched in T-lymphocytes, natural killer (NK) cells, and 
natural killer T-cells (NKT) (27,28). Polymorphonuclear leukocytes (PMN), of which 
neutrophils are predominant, are primarily recruited to the site of injury in the liver 
(29). With the exception of T-lymphocytes, all of these cells are members of the 
innate immune system. Blood, enriched of potential antigens coming from the 
gastrointestinal tract, is constantly passing the network of liver sinusoids, provides 
contact to the immune cell populations and induces immune responses against 
pathogens or immunological tolerance towards harmless antigens (26). 
In response to inflammatory signals, monocytes and macrophages are rapidly 
recruited to the liver, and these cells have similar functional profiles as KCs (30). 
Macrophages and KCs respond to pathogenic factors with production of 
proinflammatory cytokines and chemokines such as TNF-α, IL-6, Chemokine 
(C-C motif) ligand 2 (CCL2)/Monocyte chemotactic protein-1 (MCP-1) and 
Chemokine (C-X-C motif) ligand 1 (CXCL1) (KC) (31), which is the mouse 
homolog to human IL-8. In addition, also hepatocytes produce KC, 
Macrophage-Inflammatory Protein-2 (MIP-2) and Cytokine-Induced Neutrophil 
Chemoattractant-1 (CINC-1), which are all potent attractants for neutrophils (32) 
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after inflammatory stimulus. Because of the high mobility of neutrophils and their 
capacity to generate cytotoxic mediators, the main function of neutrophil 
recruitment to the site of inflammation is to rapidly eliminate invading 
microorganisms and apoptotic cells (33). Neutrophils are phagocytic leukocytes 
that represent the first line of defense during infection and injury (34). Activated 
neutrophils have high levels of myeloperoxidase, nicotinamide adenine 
dinucleotide phosphate hydrogen (NADPH) oxidase, and inducible nitric oxide 
synthase expression, resulting in their capacity to exert oxidative stress-mediated 
tissue damage (35). In the liver, the excessive inflammatory response carries the 
risk of additional tissue damage as seen during ischemia-reperfusion, acute liver 
failure, alcoholic liver disease, and viral hepatitis (36). Besides chemokines, 
adhesion molecules, such as vascular adhesion molecule (VCAM)-1 and 
intercellular adhesion molecule (ICAM)-1, play an important role in neutrophil 
infiltration and contribute to liver injury (37). 
NK cells represent a population of lymphocytes with potent cytolytic activity 
against virus-infected or tumor cells. Hepatic NK cells are regulated by Kupffer-cell 
derived cytokines, e.g. IL-12 and IL-18, as well as NKT cell-derived IL-4 (38). 
Hepatic NK cells modulate T-cell responses in the liver, promote intracellular 
changes in endothelial cells and hepatocytes (mainly via IFN-γ), and can even 
directly induce hepatocyte death or cell lysis (39). NKT cells are a subpopulation of 
extraordinary T-cells, as they express surface markers of T- and NK cells, which 
are found at unusually great quantities in the liver. From studies of experimental 
liver injury in mice after administration of the plant-derived lectin Concanavalin A 
(ConA), NKT cells have been determined as crucial factors promoting acute liver 
damage by release of IL-4, IFN-γ and direct induction of Fas-mediated hepatocyte 
apoptosis (40). 
1.4 The multifunctional cytokine IL-6 
Interleukin-6 (IL-6) is a pleiotropic cytokine with a size of 20-28 kDa depending on 
its glycosylation state (41). Primary it was found to be a B-cell differentiation factor 
that induces the production of immunoglobulins (42). Nowadays IL-6 is known to 
be crucial in regulating diverse biological activities and immune modulating 
processes. IL-6 is secreted by lymphoid cells, e.g. T-cells, B-cells, macrophages 
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and monocytes (43). It induces growth of T-cells and differentiation of cytotoxic 
T-cells by enhancing the expression of IL-2 and IL-2 receptor (44). Furthermore, 
IL-6 was demonstrated to induce differentiation of macrophages (45) and 
megakaryocytes (46). Besides its expression by lymphoid cells, IL-6 is also 
produced by various types of nonlymphoid cells, e.g. fibroblasts, keratinocytes, 
endothelial cells, adipocytes and several tumor cells (43). 
Considering its extensive ability to activate host immune responses after infection, 
IL-6 expression has to be stringently regulated and the cytokine is expressed in 
undetectable or very low levels under normal physiological conditions (47). It is 
usually secreted at local tissue sites and is released in almost all situations of 
homeostatic perturbation including acute infection, trauma and endotoxemia. IL-6 
can also become chronically elevated, resulting in the prolonged activation of its 
biological activities. A dysregulation in IL-6 values can reverse the primarily helpful 
responses into harmful conditions and has been shown to be relevant in patients 
with colon carcinoma (48,49). Moreover, IL-6 has been identified as a growth 
factor for renal cell carcinoma cells (50) and multiple myeloma cells (51). Capable 
of acting in an autocrine, paracrine, and endocrine manner, IL-6 is a pivotal 
mediator of fever (52) and regulator of hepatic acute phase response by 
stimulating hepatocytes to produce C-reactive protein, fibrinogen and serum 
amyloid A (53). 
IL-6 is a four α-helix bundle protein belonging to the family of gp130 cytokines 
including interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M 
(OSM), ciliary neurotrophic factor (CNTF), cardiotropin-1 (CT-1), cardiotrophin-like 
cytokine/neurotrophin-1/B-cell stimulating factor 3 (CLC/NNT-1/BSF-3), new 
neuropoietin (NPN), IL-27 and IL-31 (54-56). IL-6 first binds its membrane-bound 
receptor, the IL-6 receptor (IL-6R), which is not involved in signal transduction. 
Thereupon, the IL-6/IL-6R complex sequentially associates with two molecules of 
gp130. Dimerization of gp130 leads to intracellular signaling events like activation 
of JAK (Janus kinase) tyrosine kinase family members, followed by the activation 
of transcription factors of the STAT (signal transducers and activators of 
transcription) family and their subsequent transport into the nucleus. Another 
major signaling pathway for IL-6 is the Mitogen-Activated Protein Kinase (MAPK) 
cascade (57). 
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IL-6 knockout mice have been shown to develop normally but exhibit a massively 
suppressed acute phase response after tissue damage or infection. They suffer 
from impaired liver regeneration, which could be reversed by IL-6 treatment (58). 
IL-6 in the liver is mainly secreted by Kupffer cells and induces paracrine activation 
of hepatocytes after TNF-α stimulation (59). IL-6 deficient mice are impaired in 
controlling infection with facultative intracellular bacteria like Listeria 
monocytogenes and show compromised T-cell dependent antibody responses 
(60). Furthermore, IL-6 knockout mice are completely protected from collagen-
induced arthritis, a mouse model for rheumatoid arthritis (61) and they are 
resistant to experimental autoimmune encephalomyelitis (EAE) induced by 
immunization with myelin oligodendrocyte glycoprotein (MOG), an animal model 
for the demyelinating disease multiple sclerosis (62). Also cancer development 
(63), colitis (65,79), peritonitis and acute inflammation (66) are accompanied by 
altered IL-6 signaling. All in all, the phenotype of IL-6 knockout mice in diverse 
disease models underlines that IL-6 is an important cytokine involved in regulation 
of host response to infection, and that dysregulation of IL-6 contributes to several 
pathological conditions in various diseases, e.g. rheumatoid arthritis, multiple 
sclerosis and liver injury. 
1.5 IL-6 trans-signaling and soluble gp130 
Many cytokine receptors exist in a soluble form consisting of the extracellular part 
of their corresponding transmembrane receptor. Most soluble cytokine receptors 
have antagonistic properties by competing with their membrane-bound 
counterparts for the matching ligands, e.g. IL-1R, TNFR and IL-4R (67-69). In 
contrast, soluble IL-6R (sIL-6R) acts as an agonist of IL-6 activity. While gp130 is 
found on all cell types, expression of the membrane-bound IL-6R is largely 
confined to hepatocytes, neutrophils, macrophages and some lymphocyte 
subpopulations (70). Two mechanisms of IL-6 signaling are described. Binding of 
IL-6 to the membrane bound IL-6R induces the recruitment of two gp130 
molecules and the downstream activation of intracellular signalling cascades via 
gp130, a process termed classic IL-6 signaling. Therefore, cells lacking the 
membrane-bound IL-6R are not able to respond to classic IL-6 signaling. This lack 
of cell responsivness to IL-6 can be overcome by a process called IL-6 trans-
signaling. Herein, a naturally occuring soluble form of the IL-6R (sIL-6R) is found 
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in body fluids of healthy humans (25-35 ng/ml in serum), which is either produced 
by proteolytic cleavage or alternative splicing (71,72). In humans, induced 
cleavage of the IL-6R is mediated by the metalloprotease Tumor Necrosis 
Factor-alpha Converting Enzyme (TACE/ A Disintegrin And Metalloproteinase 
ADAM17), whereas constitutive shedding is dependent on ADAM10 (73). During 
IL-6 trans-signaling, sIL-6R binds to IL-6 in solution with the same affinity as 
membrane-expressed IL-6R and the complex of IL-6 and sIL-6R can stimulate 
cells lacking membrane-bound IL-6R by activating gp130. Due to the ubiquitous 
expression of gp130, the alternative IL-6 signaling pathway has important 
biological consequences since it drastically enlarges the spectrum of IL-6 target 
cells and can stimulate nearly all cells of the body. Besides, IL-6 trans-signaling 
has been shown to affect cells that already express membrane bound IL-6R. In the 
liver, hepatocytes have been demonstrated to express far more gp130 than IL-6R 
and the total number of activated gp130 molecules is increased when IL-6 and 
sIL-6R are present (74). 
In addition to the IL-6R the second component of the IL-6 receptor complex, 
gp130, also exists in a soluble form (sgp130). Relatively high circulating levels of 
sgp130 are detected in human blood (100-400 ng/ml) and sgp130 may associate 
with the IL-6/sIL-6R complex to inhibit signaling via membrane-bound gp130 (75-
78). It has been postulated that sgp130 is the natural inhibitor of IL-6-
transsignaling and that sgp130 acts as a buffer to prevent the stimulation of almost 
all cells in the body by the IL-6/sIL-6R complex (79). Alternative splicing has been 
implicated as the predominant mechanism in the cellular release of sgp130 (80). A 
designer protein, termed sgp130Fc, was constructed by fusing the complete 
extracellular region of gp130 with the Fc-part of a human IgG-antibody. The 
resulting protein is a preformed dimer and therefore strongly resembles the 
receptor conformation on the living cell. It has been shown that dimerized 
sgp130Fc is able to inhibit IL-6/sIL-6R-mediated responses with a 10-fold higher 
activity than monomeric sgp130 (79). Therefore, the application of sgp130Fc 
selectively blocks IL-6 trans-signaling without affecting classic IL-6 signaling and 
enables to distinguish between those mechanisms of signaling. So far, application 
of sgp130Fc has been shown to have beneficial effects in animal models of 
inflammation (65), autoimmunity (81) and cancer (82) pointing to the relevance of 
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IL-6 trans-signaling and the role of sgp130Fc as a powerful tool in medical 
treatment. 
signal signal
IL-6
gp130
IL-6R
sIL-6R
IL-6/sIL-6R
IL-6/sIL-6R/
sgp130Fc
classic IL-6 signaling IL-6 trans-signaling
• hepatocytes
• leukocytes
①
②
③
 
Figure 1: Schematic illustration of classic IL-6 signaling and IL-6 trans-signaling. ① Cells that express 
both gp130 and the IL-6R are responsive to IL-6 (classic signaling). ② Cells that express only gp130 can be 
activated by the complex of IL-6/sIL-6R. Activation of such cells is termed trans-signaling. ③ Molar excess of 
sgp130Fc competitive inhibits IL-6 trans-signaling by binding IL-6/sIL-6R complexes without affecting classic 
IL-6 signaling. 
 
1.6 Immune related liver damage induced by 
Concanavalin A 
The activation of T-lymphocytes occurs as initial step in the pathophysiology of 
human autoimmune liver diseases (83) or viral hepatitis (84). T-cell mediated 
hepatitis in mice can be induced by injection of the T-cell mitogenic plant lectin 
Concanavalin A (ConA), a protein originally extracted from the jack bean 
(Canavalia ensiformis). Tissue injury caused by intravenous ConA administration 
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is limited to the liver (85). When treated with ConA, mice develop an acute, partly 
apoptotic, hepatic injury that thereafter is displaced by massive necrosis (85,86). 
Acute liver failure induced by intravenous injection of ConA is characterized by 
strong leukocyte infiltration to the liver that occurs with a marked increase in levels 
of alanine aminotransferase (ALT) and asparagine aminotransferase (AST) in the 
blood shortly (8-24h) after ConA challenge (85,87-89). The cellular and molecular 
mechanisms based on ConA-induced hepatitis have been examined in great 
detail, but are still not fully understood. Although CD4+ T-cells have been shown to 
be key players in this model (85,90), there are several cell depletion studies 
showing that NKT cells (89), Kupffer cells (91) and neutrophils (87) are required to 
induce ConA-mediated liver injury. Immunregulatory cytokines play a central role 
in the pathogenesis of ConA-induced hepatitis with studies pointing to a 
proinflammatory role of TNF-α (90), IFN-γ (92), IL-12 and IL-4 (93), and a 
protective role of IL-10 (94) and MCP-1 (95). 
Injection of ConA into mice leads to an increased release of IL-6 (85,90), but the 
effects of IL-6 in this model are ambiguous. IL-6 deficient mice show a higher 
susceptibility towards ConA-induced liver injury compared to wild-type animals 
(92). Studies with anti-IL-6 antibodies reveal a more complex situation, depending 
on the time of administration. Antibody injection shortly (2.5 h) after ConA leads to 
delayed liver injury, whereas injections 24 h and 1 h before ConA result in 
increased liver damage (96). In addition, injections of recombinant IL-6 24 - 3 h 
before ConA injection completely prevented liver damage, whereas IL-6 
administration 3 - 6 h after ConA challenge resulted in enhanced liver injury (90). 
In consequence, endogenous IL-6 present before ConA administration seems to 
be hepatoprotective, while IL-6 production after ConA injection promotes liver 
damage. Furthermore, IL-6 trans-signaling has been shown to have an impact on 
neutrophil recruitment in a murine model of peritoneal inflammation. In this model, 
reconstitution of IL-6 signaling in IL-6 deficient mice with IL-6 and its soluble 
receptor corrected imbalance of neutrophil-activating CXC chemokine expression 
and suppressed neutrophil infiltration (97). In addition, neutrophil-depleted mice 
show reduced CD4+ T-cell recruitment to the liver and diminished liver injury after 
ConA administration (87). 
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However, apart from the phenotypical effects of IL-6 during ConA-induced 
hepatitis, less is known about the molecular basis. Some data indicate that the 
protective effect may be due to IL-6 induced STAT3 activation and subsequent 
suppression of IFN-γ signaling and induction of the anti-apoptotic gene B-Cell 
Lymphoma-Extra Large (Bcl-XL) (92). The harmful effect of late IL-6 application 
has been hypothesized to be due to stimulated expression of TNF-receptors on 
hepatocytes and thereby promoting the harmful role of TNF-α in ConA-hepatitis 
(98). 
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Figure 2: Suggested mechanisms of Concanavalin A induced signaling and cell activation in the liver. 
① Upon intravenous injection to mice, ConA binds to sinusoidal endothelial cells (SEC) and activates CD4+ T-
cells as well as NKT cells. ② These cells activate Kupffer cells and produce IFN-γ which seems to be 
important for activation of intrahepatic CD4+ T-cells and NKT cells. ③ MCP-1 release from Kupffer cells 
recruits further Kupffer cells/macrophages. ④ The Kupffer cells produce TNF-α that might induce apoptosis of 
SEC and hepatocytes. Moreover, neutrophils, in dependence of Kupffer cell- and SEC-derived KC are 
recruited into hepatic parenchyma ⑤ and seem to mediate liver cell necrosis together with NKT cells by 
secretion of reactive oxygen species (ROS), proteases and IL-4 ⑥. 
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1.7 Aim of this work 
A wide range of studies have shown that immune cells, cytokines and cytokine 
dependent pathways have an impact on the development of liver failure, chronic 
liver disease and hepatic inflammation (31,83,84). A dysregulation in cytokine 
interaction after liver injury can lead to massive apoptosis and necrosis which are 
pivotal results in various acute and chronic liver diseases, e.g., viral and 
autoimmune hepatitis (99,100). IL-6 pathways revealed protective functions in 
many experimental liver disease models (101,102) and therefore are an attractive 
target for a pharmacological intervention in acute and chronic liver diseases. 
Injection of ConA into mice mimics histological and pathological hallmarks of 
autoimmune and T-cell mediated hepatitis. In the present work, the role of IL-6 
classic- and IL-6 trans-signaling in ConA-induced hepatitis was investigated to 
further elucidate the complex effects of IL-6 signaling in immune related liver injury 
and in order to provide new therapeutic approaches. Since it is known that a high 
dose of ConA rapidly leads to symptoms of acute hepatitis or even death, a more 
moderate dose was used in this work to simulate the initial processes of liver-
inflammation and -injury and to analyze the influence of IL-6 signaling within the 
initial phase of processes in more detail. Furthermore, IL-6 has been shown to 
have dual functions with contrary effects in this model (90,96) and several types of 
immune cells have been shown to be necessary for the onset of liver inflammation 
in this model, but a connection between one immune cell type and IL-6 signaling 
was not made. Immune cell candidates were examined in different approaches of 
manipulated IL-6/gp130 signaling in ConA treated mice. Moreover, the relevance 
of IL-6 trans-signaling in ConA pathology was examined by using the designer 
protein sgp130Fc for in vivo experiments. Besides the relevance of IL-6 signaling 
in immune cell recruitment and initial processes in the ConA model, also the role 
of IL-6 signaling in tolerance induction towards a re-challenge with ConA was 
examined by using IL-6 deficient mice. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals used were obtained from CarlRoth (Karlsruhe, Germany), Sigma-
Aldrich (Deisenhof, Germany) or Merck (Darmstadt, Germany), unless otherwise 
stated. If not mentioned otherwise deionized water (Millipore) was used as solvent. 
2.1.2 Animals 
C57BL/6N and IL-6 deficient mice with C57BL/6N background were purchased 
from Charles River (Sulzfeld, Germany) or bred by mating in the animal facility. All 
animals were maintained at a 12-hour light-dark cycle under standard conditions 
and provided with food and water ad libitum. For all experiments 3 – 10 mice per 
group were used. 
2.1.3 Animal food 
The standard diet was obtained from SSNIFF Spezialdiäten GmbH (Soest, 
Germany). 
Standard : crude protein 19 % 
 crude fat 3.30 % 
 crude fibre 4.90 % 
 crude ash 6.70 % 
 Additives: Vitamin A: 15.000 IE/kg; Vitamin D3: 1.000 IE/kg; 
Vitamin E: 100 mg/kg; Cu: 5 mg/kg 
 
2.1.4 Recombinant proteins 
Concanavalin A (ConA) Concanavalin A, Type IV, 100 mg 
(Cat.No.: C2010, Sigma-Aldrich, Germany) 
human interleukin-6 (huIL-6) prepared and prurified as described in (139) 
soluble gp130Fc (sgp130Fc) purified from supernatant of stably transfected 
CHO-cells as described in (79) 
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2.1.5 Solutions and Buffers 
Blocking buffer (Western blot): 5 % milk powder or BSA in TBS-T 
  
Blotting buffer (Western blot): 25 mM Tris-HCl, pH 8.3 
 192 mM glycine 
 20 % (v/v) methanol 
  
Destaining solution (protein gels): 10 % (v/v) acetic acid 
 40 % (v/v) methanol 
  
Dulbecco’s PBS (1x) (ConA solutions): Cat.: H15-002 (w/o) Ca & Mg; 
PAA Laboratories, Pasching,Austria 
  
EDTA buffer (Blood preparation): 2 mM EDTA 
 0.2 % (w/v) BSA in PBS 
  
Erylysis buffer (T cell isolation): 150 mM NH4Cl 
 10 mM KHCO3 
 100 nM EDTA 
  
FACS buffer (FACS): 1 % (w/v) BSA in PBS 
 0.05 % (w/v) NaN3 
  
FACS lysing solution (Blood 
preparation): 
Cat.: 349292 
BD Bioscience, Heidelberg, Germany 
  
Histopaque 1077 (T cell isolation): Cat.: 10771, 100 ml; 
Sigma-Aldrich, Deisenhof, Germany 
  
Lysis buffer (cell lysis): 150 mM NaCl 
 2 mM EDTA 
 50 mM Tris-HCl, pH 7.4 
 1 % (w/v) Triton X-100 
 1 % (w/v) NP-40 
 1 mM Na3VO4 
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 1 mM NaF 
 1 x protease inhibitors 
  
Phosphate buffered saline (PBS): 150 mM NaCl 
 8 mM Na2HPO4, pH 7.4 
 1.7 mM NaH2PO4, pH 7.4 
  
PBS-T: 0.05 % (v/v) Tween-20 in PBS 
  
Protease-inhibitors: COMPLETETM pills, Roche 
(Mannheim, Germany) 
 Resuspending 1 pill in 50 ml Lysis 
buffer 
  
RPMI medium (T cell isolation): RPMI 1640, Cat.: E15-039 
PAA Laboratories, Pasching, Austria 
  
Running gel 10 % (15 %) (protein gels): 7.74 ml (4.5 ml) deionized water 
 5.1 ml (5.1 ml) 1.5 M Tris, pH 8.8 
 0.2 ml (0.2 ml) 10 % SDS 
 6.6 ml (9.9 ml) 30 % Acrylamide-Bis 
 0.2 ml (0.2 ml) 10 % APS 
 0.02 ml (0.02 ml) TEMED 
  
Sample-buffer (5x) (protein-gels): 10 % (w/v) SDS 
 5 % (w/v) β-mercaptoethanol 
 50 % (w/v) glycerol 
 0.13 % (w/v) bromphenol blue 
 300 mM Tris-HCl, pH 6.8 
  
Sample-buffer (2x) (protein-gels): 4 % (w/v) SDS 
 20 % (w/v) glycerol 
 5 % (v/v) β-mercaptoethanol 
 0.13 % (w/v) bromphenol blue 
 125 mM Tris-HCl, pH 6.8 
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SDS running buffer (protein-gels): 25 mM Tris-HCl, pH 8.3 
 192 mM glycine 
 0.1 % (w/v) SDS 
  
Stacking gel (4 %) (protein gels): 3.72 ml deionized water 
 0.625 ml 0.5 M Tris-HCl, pH 6.8 
 0.05 ml 10 % SDS 
 0.67 ml 30 % Acrylamid-Bis 29:1 
 25 µl 10 % APS 
 7 µl TEMED 
  
Coomassie staining (protein gels): 40 % (v/v) ethanol 
 10 % (v/v) acetic acid 
 0.1 % (w/v) coomassie R250 
  
Stripping solution (Western blot): 0.5 M NaCl 
 0.5 M acetic acid 
  
TBE (0.5x) (agarose-gels): 44.5 mM boric-acid 
 10 mM EDTA, pH 8.0 
 44.5 mM Tris-HCl 
  
Thiobarbituric acid (TBA): 67 mg in 1 ml DMSO + 9 ml H2O 
  
1,1,3,3-tetramethoxy propane (TMP): 4.167 µl in 1 ml EtOH + 49 ml H2O 
(500 µM) 
  
Trichloroacetic acid 10 % (w/v) in H2O 
  
Tris buffered saline (TBS): 10 mM Tris-HCl, pH 8.0 
 150 mM NaCl 
  
TBS-T: 1 % (v/v) Tween-20 in TBS 
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2.1.6 Primary Antibodies 
anti-β-actin: rabbit polyclonal antibody raised against the 
endogenous ß-actin 
(Cell signaling, Boston, USA) 
IB: dilution 1:1.000 (5 % BSA in TBS-T) 
  
anti-Phospho-STAT3: rabbit monoclonal antibody which detects 
endogenous levels of STAT3 only when 
phosphorylated at tyrosine 705 
(Cell signaling, Boston, USA) 
IB: dilution 1:2.000 (5 % BSA in TBS-T) 
  
anti-STAT3: mouse monoclonal antibody which detects 
endogenous levels of total STAT3 protein 
(Cell Signaling) 
IB: dilution 1:1.000 (5 % milk powder in TBS-T) 
  
anti-Ly6G/Ly6C Rat monoclonal antibody rat monoclonal antibody 
which reacts with a common epitope on Ly-6G and 
Ly-6C, previously known as the myeloid 
differentiation antigen Gr-1. The antibody recognizes 
granulocytes (neutrophils and eosinophils) and 
monocytes. 
(BD Biosciences) 
2.1.7 Secondary antibodies 
All horseradish-peroxidase coupled secondary antibodies were purchased from 
Amersham Bioscience (Buckinghamshire, United Kingdom) and used in a dilution 
of 1:5.000. 
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2.1.8 FACS antibodies 
BD Bioscience, Heidelberg, Germany 
CD11b: PE rat anti-mouse CD11b 
(Cat.: 553311) 
  
CD3e: APC-hamster anti-mouse CD3e 
(Cat.: 553066) 
  
Ly6GC: FITC anti-mouse Ly6GC 
(Cat.: 553126) 
  
NK1.1: PE mouse anti-mouse NK1.1 
(Cat.: 557391) 
  
CD69: PE-Cy7 hamster anti-mouse 
(Cat.: 552879) 
  
eBioscience, NatuTec GmbH, Frankfurt, Germany 
CD4: FITC anti-mouse 
(Cat.: 11-0042-85) 
  
2.1.9 Kits 
Greiner Kits for detection of transaminases 
(Greiner Diagnostic, Bahlingen, Germany): 
GPT (ALAT) IFCC Cat.:142000 
(5x20/2x10 ml) 
for detection of alanine 
aminotransferase 
GOT (ASAT) IFCC Cat.:141000 
(5x20/2x10 ml) 
for detection of aspartate 
aminotransferase 
 
R&D - DuoSet ELISA Development System 
(R&D Systems, Wiesbaden, Germany): 
human sgp130 Cat.: DY228 
murine IL-6 Cat.: DY406 
Materials and Methods 
19 
murine IL-4 Cat.: DY404 
KC Cat.: DY453 
MCP-1 (JE) Cat.: DY479 
murine TNF-α Cat.: DY410 
 
2.1.10 Electric devices 
FACSCanto BD Bioscience 
TECAN Rainbow 96-well UV/ELISA Reader (Railsheim, Germany) 
Olympus BX50 microscope and Olympus UC30 camera system (Tokyo, Japan) 
BioRad Power Pac 300 & 200 
BioRad Transblot SD (SemiDry) transfer cell 
BioRad Mini Trans-Blot cell  
Eppendorf Centrifuge 5415R (Heraeus Biofuge pico, Kendro Laboratory) 
Eppendorf Thermomixer 5436 
Ultrospec 3000 UV/Visible Spectrophotometer (Pharmacia Biotech) 
Jouan CR3i cooling centrifuge 
 
2.1.11 Consumables 
Disposable hydrodermic needle 100 Sterican 27 G & 21 G (Braun) 
BD Microlane 3 Needles 30 G 
Injekt-F 1 ml, single-use fine dosage syringe 2-piece (Braun) 
Nunc-Immuno Plate F96 Cert. Maxisorp, Roskilde, Denmark 
HistoBond - 76x26x1 mm Microscope Slides (Marienfeld, Lauda-Königshafen, 
Germany) 
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Sarstedt, Nümbrecht, Germany 
Petri dish 92x16 mm with cams 
Microvette Tube CB300 CH 
Micro-Test Plate 96 Well 
Tube, 15 ml & 50 ml 
Pipette tip 1000 µl blue, 200 µl yellow, 10 µl neutral 
Safe seal microtube, 2 ml 
Micro tube, 1.5 ml 
Flow cytometry tubes, 5 ml 
 
2.1.12 Software 
Microsoft Word (2000) 
Microsoft Excel (2000) 
GraphPad Prism 4 (Data editing) 
FACSDiva software, BD Bioscience (Flowcytometry detection) 
FCS Express V3 (Flowcytometry analysis) 
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2.2 Methods 
2.2.1 Animal treatment 
2.2.1.1 Animal husbandry 
Procedures involving animals and their care were conducted in conformity with 
national and international laws according to home office approved project license 
V 31272241.121-3 (41-3/06). Mice were kept at a 12-hour light-dark cycle under 
standard conditions and provided with food and water ad libitum. All mice were 
maintained under barrier conditions and were pathogen free as assessed by 
regular microbiological screening. The animals were kept at 21°C ± 2°C and 60 % 
± 5 % humidity in individually ventilated cages (IVC). 
2.2.1.2 Intravenous Concanavalin A (ConA) injection 
A stock solution with ConA (Cat.No.: C2010, Sigma, Deisenhofen, Germany) of 
10 µg/µl was diluted in sterile PBS and stored at -80°C in 1 ml aliquots until used 
for injections. Before treatment, mice were weighed, hold in a fixing-tube and mice 
tails were exposed to infrared light for one minute. Liver damage was induced by 
intravenous injection of ConA dissolved in 100 µl PBS immediately before 
treatment and applied as one dose of 12.5 or 20 µg/g body weight. Intravenous 
injection was performed using a 1 ml syringe in combination with a 30 gauge 
needle (0.3 mm x 13 mm). 
2.2.1.3 IL-6 treatment 
Mice were intravenously injected with 2 µg IL-6, 6-3 hours before ConA challenge 
for protection studies or treated with a single injection of IL-6 and sacrificed 4 h 
later for investigation of peripheral blood neutrophil level. 
2.2.1.4 Intraperitoneal injection 
200 µl sterile PBS or 200 µl sterile PBS containing antibodies (see 3.2.1.5 & 
3.2.1.6) were injected into the peritoneal cavity of mice without anesthesia. 
Solutions were prepared and loaded under a sterile fume hood. Intraperitoneal 
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injection was performed using a 1 ml syringe in combination with a 27 gauge 
needle. 
2.2.1.5 IL-6 antibody and sgp130Fc treatment 
Total IL-6 signaling was blocked with a single injection of purified rat anti-mouse 
MP5-20F3 IL-6 antibody (BD Bioscience, Heidelberg, Germany). Mice were 
intraperitoneally injected with 200 µg antibody 16 h prior to ConA injection. IL-6 
trans-signaling was blocked with a single injection of purified sgp130Fc. Mice were 
injected i.p. with 250 µg sgp130Fc 16 h prior to ConA injection. 
2.2.1.6 Neutrophil depletion 
Neutrophils were depleted using purified rat anti-mouse Ly6G/Ly6C antibody (BD 
Bioscience, Heidelberg, Germany). Mice were intraperitoneally injected with 
100 µg antibody 18 h prior to ConA challenge. Depletion was controlled with 
stainings for neutrophils on paraffin tissue sections. 
2.2.2 Serum aminotransferase measurements 
Serum alanine aminotransferase (ALT) was determined using the ALT detection 
kit (Greiner Diagnostics, Bahlingen, Germany) according to manufacturer’s 
instructions. For measurements of aminotransferas, serum was diluted 1:30 in 
PBS to stay within detection kit threshold value conditions. 
2.2.3 Enzyme-linked Immunosorbent Assay (ELISA) 
Cytokine levels were measured via ELISA using murine DuoSet ELISA Kits (R&D 
Systems, Wiesbaden, Germany) according to manufacturer´s instructions. 
Standard and serum samples were diluted with 1 % BSA/PBS. For IL-6 ELISA 
(DY406), serum was diluted 1:20 in 1 % BSA/PBS. For MCP-1 (DY479) and KC 
ELISA (DY453), serum was diluted 1:60 in 1 % BSA/PBS. Control detection of 
sgp130Fc was performed by using the human sgp130 DuoSet ELISA Kit (DY228, 
R&D Systems). For the human sgp130 ELISA, samples were diluted 1:2000 in 
1 % BSA/PBS and recombinant sgp130Fc was used as a standard with the 
highest concentration being 10 ng/ml. For murine liver IL-4 (DY404) and murine 
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TNF-α ELISA (DY410) analysis, liver lysates from homogenized liver tissue were 
used at a 10 µg/µl concentration diluted in 1 % BSA/PBS. 
2.2.4 Fluorescence-activated cell sorting (FACS) 
2.2.4.1 Flow cytometry analysis of peripheral blood granulocytes (PMNs) 
25 µl whole blood was given to 100 µl EDTA-buffer (2 mM EDTA, 0.2 % BSA in 
PBS) and immediately processed for flow cytometry stainings. Samples were 
blocked with 0.5 µl rat-serum (Jackson ImmunoResearch, Suffolk, England) and 
0.5 µl rat anti-mouse Fc block (BD Bioscience, Heidelberg, Germany) on ice for 
5 min. Whole blood cells were stained in the dark with fluorochrome directly 
conjugated mAbs: PE rat anti-mouse CD11b (BD Bioscience, Heidelberg, 
Germany, Cat.: 553311), APC-hamster anti-mouse CD3e (BD Bioscience, 
Cat.: 553066) and FITC anti-mouse Ly6GC (BD Bioscience, Cat.: 553126). 
After 30 min of incubation at 4°C, red blood cells were lysed with the FACS lysing 
solution (BD Bioscience, Cat.: 349292) for 10 min at room temperature. The cells 
were washed and resuspended in FACS buffer (PBS, 0.2 % BSA). Stained 
samples were analyzed with a fluorescence-activated cell sorter scan 
(FACScanto) cytometer (BD) and processed by FACSDiva software (BD). 
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Figure 3: Exemplary evaluation of peripheral blood neutrophils by flow cytometry. (A) Forward 
scatter/side scatter (FSC/SSC) plot showing the cellular distribution in prepared blood samples 8 h after ConA 
treatment (one representative C57BL/6 animal). Gate 1 was set to exclude both cellular debris and remaining 
erythrocytes. (B) Gate 2 quantified CD11b/Ly6G double positive cells (neutrophils) from cells selected in 
gate 1. 
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2.2.4.2 Liver-derived lymphocyte isolation and analysis by flow cytometry 
Livers were excised and pushed through a nylon mash (BD Bioscience, 40 µm cell 
strainer) in a petri dish containing 10 ml RPMI-1640 medium (PAA, Cat.: E15-039). 
The cell suspension was centrifuged at 300 g for 5 min and the supernatant was 
discarded. To get rid of erythrocytes, the cell pellet was resuspended in FACS 
lysing solution (150 mM NH4Cl, 10 mM KHCO3, 100 nM EDTA) for 10 min at room 
temperature and the supernatant was discarded after centrifugation.  
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Figure 4: Exemplary evaluation of T-cell populations by flow cytometry. (A) Forward scatter/side scatter 
(FSC/SSC) plot showing the cellular distribution in prepared liver samples 8 h after ConA treatment (one 
representative C57BL/6 animal). Lymphocyte gate (A) was set to exclude both cellular debris and remaining 
erythrocytes. (B) Gated CD3/NK1.1 double positive cells from the lymphocyte gate. (C) Gated CD3/CD4 
double positive cells from the lymphocyte gate. (D) Gated CD4/CD69 double positive cells from CD3/CD4 
gated cells.  
The cell pellet was resuspended in RPMI-1640 medium. 2 ml cell suspension was 
then overlaid onto 2.5 ml Histopaque (Sigma, Deisenhofen, Germany) and 
centrifuged for 30 min at 300 g. MNCs were collected from the interface, washed 
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in 3 ml 5 % FCS/PBS and resuspended in 50 µl 5 % FCS/PBS. Cell populations 
were stained by addition of appropriate antibodies to the suspension for 30 min at 
4°C in the dark, washed and resuspended in 500 µl 2 % FCS/PBS for flow 
cytometric analysis. NKT cell numbers were determined by using PE mouse anti-
mouse NK1.1 (BD Bioscience, Cat.: 557391) and APC-hamster anti-mouse CD3e 
(BD Bioscience, Cat.: 553066) antibodies. CD4+ T-cell activation was assessed by 
FITC anti-mouse CD4 (eBioscience, Cat.11-0042-85) and PE-Cy7 hamster anti-
mouse CD69 (BD Bioscience, Cat.: 552879) antibodies.  
2.2.5 Tissue processing and Immunohistochemistry 
2.2.5.1 Tissue processing and embedding 
Liver tissue was washed in PBS, transferred into a tissue cassette and fixed in 4 % 
formaline for 24 h at 4°C. After fixation, tissues were transferred to 70 % ethanol 
and cassettes were put through a series of graded EtOH baths to dehydrate the 
tissues. Subsequently the cassettes were transferred to xylene and thereafter to a 
hot paraffin bath: 
• 70 % Ethanol 60 min (x1) 
• 95 % Ethanol 45 min (x2) 
• 100 % Ethanol 45 min (x2) 
• Xylene 60 min (x2) 
• Paraffin (65°C) 30 min. (x1) 
• Paraffin (65°C) over night (x1) 
• Paraffin (65°C) 90 min (x1) 
Tissues processed into paraffin were embedded by placing the entire cassette on 
a heat block. Also warm metal block molds were put on the hot plate. The 
paraffinized specimens were placed with the cut surface down towards the bottom 
of the mold. Hot paraffin was added to the mold from a paraffin pot. When the 
tissue was in the desired orientation the labeled tissue cassette was added on top 
of the mold as a backing. Subsequently the mold was taken off the hot plate and 
transferred onto a cold aluminum plate in a freezer. When the wax was completely 
cooled and hardened (~5 min) the paraffin block was popped out of the mold. 
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2.2.5.2 Sectioning tissues 
Blocks to be sectioned were placed face down on ice for 10 min. The block was 
inserted into the microtome chuck so the wax block faced the blade and was 
aligned in the vertical plane. 5 µm sections were cut and picked up with forceps or 
a fine paint brush and floated on the surface of the 37ºC water bath. Afterwards, 
the sections were floated onto the surface of clean glass slides. 
2.2.5.3 Hematoxylin & Eosin staining 
Tissue sections were shortly incubated in Gill3 Hematoxylin (Thermo Scientific, 
Cheshire, UK), differentiated in 0.5 % acetic acid, rinsed in water and stained with 
Giemsa’s azur eosin methylene blue solution (Merck, Darmstadt, Germany).  
2.2.5.4 Neutrophil and pSTAT3 staining 
Staining for neutrophils was carried out using a monoclonal rat anti-mouse 
neutrophil antibody (AbDserotec, Düsseldorf, Germany) diluted 1:2000 in sample 
diluent (Dako, Glostrup, Denmark). After incubation with biotinylated polyclonal 
rabbit anti-rat antibody (Dako, Glostrup, Denmark) and EnVision-HRP (Dako, 
Glostrup, Denmark) the signal was developed with AEC Substrate (Dako, 
Glostrup, Denmark) and samples were counterstained with Shandon Gill3 
Hematoxylin (Thermo Scientific, Cheshire, UK). Staining for STAT3 
phosphorylation was carried out using anti-mouse pSTAT3 antibody (Cell 
signaling, Danvers, MA) diluted 1:3,000 and the signal was amplified using the 
Tyramide Signal Amplification kit (Perkin Elmer, Boston, MA), developed with AEC 
substrate and counterstained with Shandon Gill3 Hematoxylin. 
2.2.5.5 Quantification of Immunohistology 
Magenta nuclear color reaction indicated STAT3 phosphorylation or positive 
stained neutrophilic cells in liver sections. Infiltrated neutrophils from liver sections 
of mice were quantified and positive cells were counted from 10 random high-
powered fields with 20x magnification from 3-5 mice of each group. Cells stained 
positive for pSTAT3 in immunostained liver sections were also quantified by 
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counting 10 random high-powered fields of 20x magnification photomicrographs 
from 3-5 mice of each group. 
2.2.6 Protein-biochemical methods 
2.2.6.1 Cell lysis 
50-100 mg of liver tissue originating from one murine liver lobe was given to 500 µl 
lysis buffer (500 mM NaCl, 50 mM Tris, pH7.4, 0.1 % SDS, 1 % NP-40) and was 
homogenized by 4-6 precellys ceramic balls using the precellys 24 shaker-system. 
Afterwards, reaction tubes containing the homogenized solution were constantly 
agitated for 1 h at 4°C. Subsequently, debris was removed by centrifugation 
(16,000 x g, 30 min, 4°C) and the supernatant was stored at -20°C. 
2.2.6.2 Determination of protein concentration (BCA) 
The protein concentration of cell lysates was determined using the BCA kit 
(Pierce). Solutions A and B were mixed (ratio 1:50) to give the BCA solution. Cell 
lysates were diluted 1:10 with PBS. 10 µl of the diluted cell lysate were mixed with 
200 µl BCA solution in microtiter plates and incubated for 30 min at room 
temperature. A BSA standard curve was co-incubated ranging from 100 µg/µl to 
2 µg/µl. The extinction of the samples was determined at 562 nm in a microtiter 
plate reader (Tecan, Maennedorf, Switzerland). 
2.2.6.3 SDS-polyacrylamide gel electrophoresis 
Separation of proteins was performed by discontinuous SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Mini-Protean III system (BioRad). The size 
of the running and stacking gels was as follows: 
Running gel: height 4.5 cm, thickness 1 mm 
 10 % or 15 % acrylamide solution 
  
Stacking gel: height 1 cm, thickness 1 mm 
 5 % acrylamide solution 
 10-well combs 
 
Materials and Methods 
28 
After complete polymerization of the gel, the chamber was assembled as 
described by the manufactures protocol. Up to 20 µl samples were loaded in the 
pockets and the gel was run at constant 120 V for 5 min and then at 180 V for the 
remainder. The gel run was stopped when the bromphenol blue line reached the 
bottom of the gel. Gels were subsequently subjected to Western blotting. 
2.2.6.4 Western blot analysis 
Proteins were transferred from the SDS-gel on a PVDF membrane (Amersham-
Biosciences, Buckinghamshire, U.K.) using a MINI TRANSBLOT-apparatus 
(BioRad). The blotting sandwich was assembled as described in the manufactures 
protocol. Proteins were transferred electrophoretically at 4°C in blotting-buffer at 
3-4 mA/cm2 for 75 min. 
2.2.6.5 Immunochemical detection of proteins on PVDF membranes 
After electrophoretic transfer, the protein loaded membranes were removed from 
the sandwiches and placed with the protein-binding side up in plastic vessels. 
Membranes were immediately incubated with 25 ml blocking buffer for 1 h at RT. 
Afterwards, the primary antibody was added in the appropriate dilution overnight at 
4°C. The primary antibody was removed by washing the membrane 3 x 10 min 
with TBS-T. The appropriate secondary antibody was applied for 1 h at RT and 
afterwards the membrane was washed again 3 x 10 min with TBS-T. 
Immunoreactive bands were visualized using the enhanced chemiluminescence 
detection system (Amersham-Biosciences, Buckinghamshire, U.K.). Therefore the 
membrane was soaked for 3 min in detection solution and afterwards placed 
between two transparent plastic foils. The membrane was exposed and analyzed 
with the chemiluminescense camera system LAS-100 (Fujifilm, USA) for defined 
time periods. 
2.2.7 Statistical analysis 
Data are expressed as mean values ± SD; 3-10 mice were used per experimental 
group. Statistical analysis was performed by using a Student’s unpaired t test 
(http://www.physics.csbsju.edu/stats/t-test.html). A p-value below 0.05 was 
considered statistically significant and denoted with one asterisk (*), whereas a 
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p-value below 0.01 was indicated with two asterisks (**) or (***) for a p-value below 
0.001 (*p≤0.05; **p≤0.01 and ***p≤0.001), respectively. 
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3 Results 
3.1 Impact of endogenous IL-6 in ConA-induced hepatitis 
3.1.1 Highly dosed ConA application is accompanied by high mortality 
Intravenous injection of 20 µg/g dosed ConA resulted in lower alanine 
transaminase (ALT) serum levels in IL-6 deficient mice compared to control mice 
8 h after treatment (Fig. 5A). On the contrary, 24 h after application of 20 µg/g 
ConA IL-6 deficient mice exhibited increased ALT levels compared to control 
animals (Fig. 5B). Similar ALT levels in both groups of control mice and increased 
ALT levels from 8 to 24 h in IL-6 deficient mice indicated a time dependent 
development of liver damage and an important role of endogenous IL-6 during the 
onset of ConA-mediated hepatitis. Besides this observations, 30-40 percent of all 
used mice died within 8 or 24 h after application of 20 µg/g ConA (Tab.1). 
Therefore a lower dose of ConA (12.5 µg/g mouse) was used for all further 
experiments. 
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TABLE 1.  Mortality rate after high dosage ConA (20 µg/g)
Experiment
number Genotype
Experiment
duration
N
beginning
N
dead
1
2
IL-6-/-
IL-6-/-
wild-type
wild-type
8 h
24 h
9
8 2
3
36
7 4
A B
 
Figure 5: High dosage ConA induced massive liver damage and lethality. Groups of male C57BL/6 mice 
and IL-6 deficient mice were challenged with a single injection of ConA (20 µg/g, i.v.) for (A) 8 hours and (B) 
24 hours and ALT levels were determined from blood serum. The used number of animals and the number of 
dead animals during experimental duration is given in table 1 (Tab. 1). Up to 60 percent of all treated animals 
died within the experiment duration before samples could be taken. Values are shown as means ± SEM. 
*p≤0.05 and **p≤0.01. 
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3.1.2 Abrogation of classic IL-6 signaling but not IL-6 trans-signaling 
reduces ConA-mediated liver hepatitis 
Intravenous administration of a single dose of ConA (12.5 µg/g mouse) resulted in 
lower alanine transaminase (ALT) serum levels in IL-6 deficient mice compared to 
control mice 8 h after treatment (Fig. 6A). However, 24 h and and 48 h after ConA 
application the amount of hepatocyte derived ALT in the serum of IL-6 deficient 
mice and control animals was comparable.  
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Figure 6: IL-6 signaling alters liver damage in ConA treated mice. Mice were intravenously injected with 
12.5 µg/g ConA. ALT levels were determined form blood serum of (A) IL-6-deficient mice, (B) wild-type mice 
pretreated with an neutralizing anti-IL-6 antibody (200 µg/mouse, i.p.) 16 h before ConA injection and (C) wild-
type mice pretreated with sgp130Fc (250 µg/mouse, i.p.) 16 h before ConA injection. C57BL/6 control animals 
remained untreated (A), were i.p. injected with control IgG (B) or PBS (C) 16 h before ConA treatment. 
Representative photomicrographs of H&E stained sections from (D) IL-6-deficient mice, (E) anti-IL-6 antibody 
pretreated mice and (F) sgp130Fc pretreated mice, 48 h after ConA injection. Massive necrosis is indicated by 
white arrows. Values are shown as mean ± SEM. **p≤0.01.  
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Nevertheless, histological examination of the liver by H&E staining displayed fewer 
and smaller areas of liver damage 48 h after ConA administration in IL-6 deficient 
mice compared to control mice (Fig. 6D). Generally, there was some variation in 
ALT levels, e.g. 24 h after ConA application (Fig. 6A). In addition, also ALT level 
variations between two sets of experimental data were noted (Fig. 6A&B). Still, 
liver damage in mice, which received a single injection of neutralizing anti-IL-6 
mAbs 16 h before ConA was reminiscent of that found in IL-6 deficient mice 
(Fig. 6B&D). In contrast, liver damage in mice injected with sgp130Fc 16 h before 
ConA was not altered compared to control mice (Fig. 6C&F), indicating that initial 
ConA-mediated liver damage is at least partially mediated by IL-6 classic signaling 
but not by IL-6 trans-signaling. 
Serum IL-6 levels were determined to survey an IL-6 induction during ConA-
mediated liver damage. IL-6 levels were found to be strongly elevated and 
comparable in all groups of control mice 8 h after ConA application and decreased 
24 h and 48 h after ConA challenge (Fig. 7A-C).  
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Figure 7: Serum IL-6 and sgp130Fc level after ConA application. IL-6 level from (A) IL-6-deficient mice, 
(B) anti-IL-6 antibody pretreated mice and (C) sgp130Fc pretreated mice were determined by ELISA after 
ConA challenge. (D) Serum sgp130Fc level in sgp130Fc pretreated mice after ConA injection. 
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In contrast, 3 different patterns of IL-6 levels were observed in IL-6 deficient-, anti-
IL-6 mAb- and sgp130Fc-treated mice. As expected, no IL-6 was detectable in IL-6 
deficient mice (Fig. 7A). Anti-IL-6 mAb treated mice exhibited slightly increased 
levels of IL-6 compared to control mice during all points of investigation (Fig. 7B), 
whereas sgp130Fc treated mice revealed a 3-fold increase of serum IL-6 8 h after 
ConA injection (Fig. 7C). Application of sgp130Fc was evidenced by measurement 
of serum sgp130 levels (Fig. 7D). However, in consideration of the observed liver 
damage severity, different IL-6 levels do not seem to be responsible since ALT 
level of IL-6 deficient and anti-IL-6 mAb treated mice were comparable and also 
IL-6 level in sgp130Fc treated mice and their corresponding control animals were 
similar. 
 
3.1.3 Abrogated classic IL-6 signaling caused reduced STAT3 
phosphorylation in the liver during ConA-mediated hepatitis 
The expression of the IL-6R is limited to cell populations such as lymphocytes and 
hepatocytes whereas gp130 is ubiquitously expressed. Phosphorylation of STAT3 
is one major downstream signaling event in IL-6 stimulated cells. Therefore, the 
phosphorylation status of STAT3 in hepatocytes was analyzed to elucidate 
whether IL-6-signaling in the liver is mediated by IL-6 classic or trans-signaling 
during ConA-induced processes. 8 h after ConA-challenge significantly reduced 
STAT3 phosphorylation was observed in IL-6 deficient mice and anti-IL-6 mAb 
treated mice but not in sgp130Fc treated mice compared to their respective control 
animals (Fig. 8A-C). Although numbers of pSTAT3 positive cells from 
immunostained liver sections (Fig. 8B) revealed variations between the control 
groups depending on the severity of induced liver damage (compare Fig. 6A&B), 
these results demonstrate that during ConA-mediated hepatitis the liver is a target 
of classic IL-6 signaling and not of IL-6 trans-signaling, although the liver clearly 
has the potential to conduct IL-6 trans-signaling (103,104). 
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Figure 8: STAT3 phosphorylation in the liver 8 h after ConA. (A) Western blot analysis for pSTAT3 and 
STAT3 from liver lysates of mice, treated as described in Figure 4. Mice were sacrificed 8 h after ConA 
injection, liver extracts were prepared and Western blot analysis was performed. (B) Quantification of pSTAT3 
positive cells, 8 h after ConA injection. Positive cells were counted from 10 random high-powered fields from 3 
mice of each group and are shown as x-fold increase compared to their corresponding control mice. 
(C) Representative photomicrographs of liver sections from corresponding mice, stained for pSTAT3, 8 h after 
ConA treatment. Cells positively stained for pSTAT3 are exemplarily indicated by black arrows. Values are 
shown as means ± SEM. *p≤0.05 and **p≤0.01. 
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3.1.4 Reduced liver T-cell infiltration and activation in IL-6 deficient 
mice after ConA treatment 
Activation of T-lymphocytes is a critical process in the pathophysiology of human 
autoimmune and viral hepatitis. CD4+ T-cells and NKT cells, which have been 
shown to play an important role in ConA-induced hepatitis (92) were examined in 
IL-6 deficient mice and mice with blocked IL-6 trans-signaling due to injection of 
sgp130Fc before ConA treatment. Levels of CD4+ cells from total liver 
lymphocytes were determined by FACS analysis of CD3+/CD4+ double positive 
cells. Levels of NKT cells from total liver lymphocytes were determined by gating 
NK1.1+/CD3+ double postive cells. The levels of activated CD4+ T-cells from 
CD3+/CD4+ T-cells in the liver was examined by using the early activation marker 
CD69+. Administration of ConA caused a significant increase of T-cell populations 
in all mice used (Fig. 9A-F).  
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Figure 9: Relative T-cell populations in the liver 8 hours after ConA. Male C57BL/6 wild-type mice (n=5) 
and IL-6 deficient mice (n=5) were challenged with ConA (12.5 µg/g, i.v.) for 8 h. Control mice remained 
untreated. (A) Percentage of activated CD4+/CD69+ T-cells from CD3+/CD4+ T-cells. (B) Percentage of 
CD3+/CD4+ T-cells from total hepatic lymphocytes. (C) Levels of NKT cells from total liver lymphocytes. 
(D) Percentage of activated CD4+/CD69+ T-cells from CD3+/CD4+ T-cells. (E) Percentage of CD3+/CD4+ 
T-cells from total hepatic lymphocytes. (F) Levels of NKT cells from total liver lymphocytes in sgp130Fc 
treated mice after ConA. Values are given as means ± SEM. *p≤0.05 and ***p≤0.001. 
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However, percentages of CD3+/CD4+ T-cells and NKT cells from total liver-
lymphocytes were reduced in IL-6 deficient mice compared to their wild-type 
control animals (Fig. 9B&C). In addition, levels of activated CD4+/CD69+ T-cells in 
the liver were reduced in IL-6 deficient mice (Fig. 9A), suggesting a role of IL-6 on 
activation of CD4+ T-cells and the presence of NKT cells (Fig. 9A-C). 
Nevertheless, no differences in levels of activated CD4+ T-cells, CD3+/CD4+ 
T-cells and NKT cells in sgp130Fc treated and control mice were found 
(Fig. 9D-F). These findings suggest that IL-6 dependent mechanisms for T-cell 
recruitment to the liver and activation of T-cells after ConA administration are 
mediated via IL-6 classic signaling and not trans-signaling. 
 
3.1.5 IL-6 deficiency is accompanied by reduced numbers of liver 
neutrophils during ConA-mediated hepatitis 
Neutrophil transmigration has been shown to be an IL-6 dependent process in 
many mouse models (105,106). In addition, neutrophils were shown to have an 
essential role in ConA-mediated hepatitis (87,107). Investigation of liver slides 
immunostained for neutrophils 8 h after ConA administration revealed reduced 
neutrophil numbers in IL-6 deficient mice and mice treated with anti-IL-6 mAb 
compared to sgp130Fc treated mice and control mice (Fig 10A). Quantification of 
positively immunostained neutrophils showed a 1.8 fold reduction of accumulated 
neutrophils in the liver of IL-6 deficient and anti-IL-6 mAb treated mice, whereas 
mice treated with sgp130Fc revealed no reduction of liver neutrophils compared to 
control mice (Fig. 10B). These data indicate that neutrophil recruitment after ConA 
challenge is mediated by classic IL-6 signaling but not by IL-6 trans-signaling. 
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Figure 10: Neutrophil infiltration in the liver after ConA treatment. Groups of mice were treated as 
described in Figure 6. (A) Representative photomicrographs of liver slides from corresponding mice 
immunostained for neutrophils, 8 h after ConA treatment. Neutrophilic cells are exemplarily indicated by black 
arrows. (B) Quantification of infiltrated neutrophils from liver sections of corresponding mice, 8 h after ConA 
injection, counted from 10 randomly selected high-powered fields from 3 mice of each group. Values are 
shown as means ± SEM. **p≤0.01 and ***p≤0.001. 
 
3.1.6 Neutrophil depletion completely protects from ConA induced 
liver injury 
As previously reported (87), neutrophil depletion protected mice from ConA-
mediated hepatitis. In fact, mice pretreated with neutrophil depleting Ly6G mAb 
showed normal serum ALT levels at all time points after ConA application 
(Fig. 11A). Furthermore, levels of two prominent members of chemoattractant 
cytokines, neutrophil-attracting chemokine KC and monocyte chemoattractant 
protein-1 (MCP-1) were examined. The levels of KC in neutrophil depleted mice 
were unaffected compared to control mice (Fig. 11C).  
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Figure 11: Neutrophil depletion protects from ConA induced liver damage. Groups of male C57BL/6 
wild-type mice (n=5) were either injected (i.p.) with anti Ly6GC antibody (100 µg/mouse) or i.p. injected with 
100 µl control PBS, 18 h prior to ConA i.v. injection (12.5 µg/g). (A) Blood samples were taken at the time 
points indicated and ALT levels were determined from blood serum. (B) Serum IL-6 levels, (C) serum KC 
levels and (E) serum MCP-1 levels were determined by ELISA. (D) Hepatic IL-4 levels were determined from 
liver lysates by ELISA, 8 h after ConA injection. Values are shown as means ± SEM. *p≤0.05 and **p≤0.01. 
Accumulated neutrophils in the liver have been shown to inhibit the production of 
MCP-1 by Kupffer cells during Listeria monocytogenes infection (106) and MCP-1 
has protective effects in ConA-mediated liver injury (95). Neutralization of MCP-1 
led to an increase in liver damage and increased IL-4 secretion from activated 
liver-resident NKT cells, which exhibit proinflammatory effects in ConA-treated 
mice (95,108). Indeed, neutrophil depleted mice showed higher MCP-1 levels as 
compared to control mice during ConA-mediated hepatitis (Fig. 11E) and reduced 
IL-4 expression in the liver (Fig. 11D). Serum levels of IL-6 were not found to be 
significantly different in neutrophil depleted mice and control animals 8 h after 
ConA injection (Fig. 11B). These data suggest a direct connection between 
neutrophil infiltration, MCP-1 release and IL-4 expression during ConA-mediated 
hepatitis. 
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Figure 12: Distribution of lymphocytes in neutrophil depleted mice after ConA treatment. Mice were 
treated as described in Figure 8. (A) Representative photomicrographs of liver slides from corresponding mice 
H&E stained and immunostained for neutrophils, 48 h after ConA treatment. Neutrophilic cells are indicated by 
black arrows. Necrotic areas are indicated by white arrows. (B) Neutrophils in peripheral blood 8 h after ConA 
injection. (C) Percentage of activated CD4+/CD69+ T-cells from CD3+/CD4+ T-cells. (D) Percentage of 
CD3+/CD4+ T-cells from total hepatic lymphocytes. (E) Levels of NKT cells from total liver lymphocytes. Values 
are given as means ± SEM. ***p≤0.001. 
Control analysis of neutrophil accumulation in the peripheral blood of depleted and 
ConA treated mice showed almost no neutrophils (Fig. 12B). In line, 
immunohistological investigation 48 h after ConA treatment showed no liver 
damage in neutrophil depleted mice but massive necrosis in control animals with 
neutrophils specifically localized at the border areas of liver damage (Fig. 12A). 
However, 48 h after ConA application also depleted mice displayed neutrophils 
inside the liver suggesting that reinfiltration takes place and neutrophils are only 
harmful during the first hours of ConA-induced hepatitis. Surprisingly, no 
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differences in hepatic CD4+ T-cell and NKT cell levels were observed in neutrophil 
depleted mice compared to control animals (Fig. 12C-E), suggesting that the 
presence of activated neutrophils is not involved in recruitment and activation of 
T-lymphocytes after ConA challenge. 
 
3.1.7 IL-6 deficiency results in increased hepatoprotective MCP-1 and 
decreased hepatodestructive IL-4 during ConA-mediated 
hepatitis 
Since MCP-1 levels were increased and IL-4 level were reduced in neutrophil 
depleted mice during ConA-mediated hepatitis (Fig. 11D&E), corresponding 
cytokine levels were also analyzed in IL-6 deficient mice, anti-IL-6 mAb treated 
mice and sgp130Fc treated mice. 8 h after ConA-induced hepatitis MCP-1 levels 
were also significantly elevated in IL-6 deficient mice and mice treated with anti-
IL-6 mAb but not with sgp130Fc (Fig. 13A). Even though abrogated classic IL-6 
signaling led to diminished neutrophils in the liver, the neutrophil attracting 
chemokine KC was not altered (Fig. 13B). Reduction of liver-expressed IL-4 and 
TNF-α in IL-6 deficient and in anti-IL-6 mAb but not in sgp130Fc treated mice 8 h 
after ConA injection indicated that classic IL-6 signaling positively regulated IL-4 
and TNF-α production (Fig. 13C-E). These findings suggested that reduced 
neutrophil numbers, increased MCP-1 level and reduced IL-4 level in the liver are 
crucial factors for the reduced ConA mediated liver damage in mice with blocked 
classic IL-6 signaling. 
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Figure 13: Inflammatory cytokine and chemokine levels in ConA challenged mice. Groups of mice were 
treated as described in Figure 6. (A) Serum MCP-1 levels and (B) serum KC levels were determined by 
ELISA. (C) Hepatic IL-4 levels and hepatic TNF-α levels from (D) IL-6 deficient and (E) anti-IL-6 antibody 
treated mice were determined from liver lysates by ELISA, 8 h after ConA injection. Values are shown as 
means ± SEM. *p≤0.05 and ***p≤0.001. 
 
3.1.8 Deficiency of classic IL-6 signaling caused reduced levels of 
circulating neutrophils in the peripheral blood during ConA-
mediated hepatitis 
Neutrophil depleted mice displayed no elevated liver damage and no neutrophils in 
the peripheral blood after ConA treatment (Fig. 11A & Fig. 12B). In addition, 
reduced levels of circulating neutrophils in the peripheral blood were observed in 
IL-6 deficient mice during Listeria monocytogenes infection (109), indicating that 
endogenously produced IL-6 is required to mount an efficient neutrophilia. 
Therefore, also IL-6 deficient mice, anti-IL-6 mAb treated mice and sgp130Fc 
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treated mice were examined for neutrophil level in the peripheral blood 8 h after 
ConA application. An 5.4 fold increase of circulating neutrophils in the peripheral 
blood was observed in wild-type mice compared to untreated controls, which was 
reduced in IL-6 deficient mice (2.4 fold) and mice treated with anti-IL-6 mAb 
(3.2 fold) but not with sgp130Fc (5.8 fold) (Fig. 14A). These observations point out 
that classic but not IL-6 trans-signaling is responsible for neutrophilia during 
immune responses such as induced in ConA-mediated hepatitis. 
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Figure 14: Neutrophil accumulation in the peripheral blood of ConA and IL-6 injected mice. Neutrophils 
in peripheral blood were determined by flow cytometry. (A) Neutrophils in peripheral blood determined 8 h 
after ConA injection. Mice were pretreated as described before and challenged with ConA (12.5 µg/g, i.v.) for 
8 h. (B) Neutrophils in peripheral blood, 4 h after cytokine injection. 2 µg/mouse IL-6 with or without 
200 µg/mouse anti-IL-6 mAb or 250 µg/mouse sgp130Fc were injected i.v. in mice (n=4). Values are shown as 
means ± SEM. *p≤0.05, **p≤0.01 and ***p≤0.001. 
Intravenous injection of IL-6 has been described to induce neutrophilia with an 
early phase caused by mobilization of neutrophils into the peripheral blood from 
the marginated pool of the vascular endothelium and a late phase resulting from 
an accelerated bone marrow release of neutrophils (52,110). Thus, IL-6 with or 
without anti-IL-6 mAb or sgp130Fc was injected i.v. and levels of circulating 
neutrophils in the peripheral blood were analyzed after 4 h. Indeed, IL-6 treatment 
induced neutrophilia, which could be specifically inhibited with anti-IL-6 mAb but 
not with sgp130Fc (Fig. 14B), indicating that neutrophilia is mediated by classic 
IL-6 signaling but not by IL-6 trans-signaling. Taken together, these findings 
indicate that neutrophilia strongly contributes to the onset of liver damage and is 
primarily mediated by IL-6 during ConA induced hepatitis. 
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3.2 The dual mode of IL-6 action in ConA-induced 
hepatitis 
3.2.1 IL-6 treatment before ConA challenge protects from liver damage 
It has been shown that injections of recombinant IL-6, 24 - 3 h before ConA 
injection, completely prevented liver damage, whereas IL-6 administration 3 - 6 h 
after ConA challenge resulted in enhanced liver injury (90). In consequence, 
endogenous IL-6 present before ConA administration seems to be 
hepatoprotective, while IL-6 production after ConA injection promotes liver 
damage. Indeed, intravenous injection of recombinant IL-6, 3 h before ConA 
treatment, prevented liver damage and ALT serum increase compared to control 
mice (Fig. 15A). In addition also serum levels of MCP-1 (Fig.15B) and KC 
(Fig. 15C) were reduced in IL-6 treated mice. Since IL-6 serum levels were not 
altered in IL-6 protected mice after ConA challenge (Fig. 15D), these findings 
suggest a low potential of endogenous IL-6 for the induction of inflammatory 
processes in this mice. However, IL-6 has been shown to have an impact on 
neutrophil recruitment by soluble IL-6 receptor signaling during inflammation (97). 
In addition, neutrophil-depleted mice showed reduced CD4+ T-cell recruitment to 
the liver and diminished liver injury after ConA administration (87). Suprisingly, no 
differences in levels of blood- and liver-accumulated neutrophils were observed 
(Fig. 15E&F), indicating that the hepatodestructive potential of neutrophils after 
injection of recombinant IL-6 was diminished. Some data indicate that the 
protective effect of IL-6 is due to STAT3 activation and subsequent suppression of 
IFN-γ signaling and induction of Bcl-XL (92). In line, IL-6 has been shown to induce 
expression of the anti-apoptotic hepatic proteins FLIP and bcl-2 after Fas agonist 
treatment (111). Therefore, induction of bcl-2 and FLIP expression in the liver was 
examined in IL-6 treated mice and control mice 4 h after ConA injection. No 
noticeable differences were found in expression of bcl-2 and FLIP proteins 
(Fig. 15G), indicating that the protective effect of IL-6 treatment before ConA 
challenge might not be due to induction of anti-apoptotic events. 
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Figure 15: ConA-mediated hepatitis after IL-6 pretreatment. 3 h before ConA injection mice were 
intravenously injected with 2 µg recombinant IL-6. (A) Serum ALT levels, (B) serum MCP-1 levels, (C) serum 
KC levels and (D) serum IL-6 levels in IL-6 pretreated mice and control mice 8 h after ConA challenge. Levels 
of neutrophils in peripheral blood (E) and liver (F) 8 h after ConA injection. (G) Western blot analysis of anti-
apoptotic bcl-2 and FLIP (2 splice variants shown) expression in the liver 4 h after ConA application. 
 
3.2.2 IL-6 deficiency impairs ConA tolerance and results in 
reinfiltration of neutrophils 
It has been shown that 8 days after a first ConA injection of ConA, mice become 
tolerant against ConA restimulation (112). Since IL-6 deficient mice showed 
reduced ConA-mediated liver damage, also tolerance induction towards ConA was 
investigated in IL-6 deficient mice. 8 days after the first ConA challenge, mice were 
rechallenged with ConA. IL-6 deficient and control mice showed no increase of 
ALT level 8 h after the second ConA challenge. However, 24 h after the second 
ConA-challenge IL-6 deficient mice showed increased blood ALT level (Fig. 16A) 
and increased liver damage as shown by immunohistochemical analysis, whereas 
control mice remained unaffected (Fig. 16C). suggesting that IL-6 plays a major 
role in ConA tolerance development. Evidence for the importance of IL-6 signaling 
during ConA tolerance is also given by IL-6 levels in the serum of re-treated mice. 
An abolished re-release of endogenous IL-6 to the serum in protected mice 8 and 
Results 
45 
24 h after ConA re-treatment reflects the dual mode of IL-6 action with initial 
harmful and long-term protective effects (Fig.16B). 
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Figure 16: Liver damage and immune cell populations after ConA rechallenge. (A) Nine days after ConA 
treatment (12.5 µg/g, i.v.) wild type (n=5) and IL-6 deficient (n=5) were challenged with a second injection of 
ConA (12.5 µg/g, i.v.) for 24 h and ALT levels were determined. (B) Serum IL-6 level determined by ELISA.  
(C) H&E stained and neutrophil immunostained sections from corresponding mice 24 h after second ConA 
injection. Necrotic areas are indicated by white arrows. Neutrophilic cells are indicated by black arrows. 
(D) Infiltrated neutrophils were quantified by counting 10 random high-powered fields from 3 mice of each 
group. Levels of (E) activated CD4+ T-cells, (F) CD3+/CD4+ T-cells and (G) NKT cells estimated by flow 
cytometry analysis. Values are shown as means ± SEM. *p≤0.05; **p≤0.01 and ***p≤0.001. 
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Surprisingly, 24 h after rechallenge with ConA, tolerant mice showed 1.7 times 
less neutrophils in the liver compared to the first ConA-challenge, whereas IL-6 
deficient mice had 2.2 times higher numbers of liver neutrophils than control mice 
(Fig. 16C&D). In line to the first challenge with ConA, percentages of CD3+/CD4+ 
T-cells and NKT cells from total liver-lymphocytes were reduced in control mice 
and in IL-6 deficient mice (Fig. 16F&G) but levels of activated CD4+/CD69+ from 
CD3+/CD4+ T-cells were increased in IL-6 deficient mice (Fig. 16E). These findings 
emphasize the dual role of IL-6 in ConA-mediated processes and also suggest 
mechanisms other than IL-6 signaling, for neutrophil and T-cell activation in ConA 
tolerance. 
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4 Discussion 
4.1 Endogenous IL-6 contributes to liver damage during 
the onset of ConA-mediated hepatitis 
IL-6 is a multifunctional cytokine involved in pro- and anti-inflammatory processes 
during disease progression. Intravenous injection of ConA into mice induced 
massive tissue damage limited to the liver and led to an increased release of IL-6. 
IL-6 was shown to play a dual role in ConA-induced hepatitis. Exogenous IL-6 has 
been reported to protect against the disease, when IL-6 was injected 24 to 3 h 
before ConA-induced liver injury, but to amplify disease manifestations when IL-6 
was administered 3 to 6 h after ConA injection (90,113,114). In hepatocytes, 
exogenous IL-6 induced the production of acute-phase proteins, and serum 
amyloid A (SAA) has been found to be protective for hepatocytes in ConA-
mediated hepatitis (115).  
The role of endogenous IL-6 during ConA-mediated hepatits has been examined 
by two different approaches in IL-6 deficient mice and mice treated with anti-IL-6 
antibodies at various time points before and after ConA treatment (92,96). These 
reports claim that IL-6 deficient mice were more susceptible to liver injury after 
high-dose application of ConA (92). From antibody studies it was concluded that 
endogenous IL-6 present before ConA challenge as well as that induced in the 
very early phase after ConA injection was hepatoprotective. IL-6 produced beyond 
the early phase was hypothesized to be harmful to hepatocytes (96). In both 
studies a 20 µg/g ConA dosage was used to examine the role of IL-6. 24 h after 
ConA injection IL-6 deficient mice were found to have increased ALT levels 
compared to wild-type mice. Indeed, own results 24 h after high dosed ConA 
application mice showed increased ALT levels compared to control animals 
(Fig. 5B). However, a closer inspection of liver damage 8 h after high dosed ConA 
application revealed significantly reduced ALT levels in IL-6 deficient mice 
compared to wild-type mice (Fig. 5A). Furthermore, application of 20 µg/g ConA 
induced massive lethality in mice (Fig. 5, Tab.1). Since liver diseases, mimicked 
by ConA application like autoimmune hepatitis and viral hepatitis last from days to 
months before they become life-threatening, a dosage of 20 µg/g seemed to be 
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inadequate for investigation. In addition, ConA administration has been shown to 
induce prominent intrasinusoidal hemostasis with massive erythrocyte 
agglutination (116), which might be overwhelming in high dosed ConA approaches 
and might also induce lethality independent of toxic liver effects. Therefore, a 
lower dose of ConA with 12.5 µg/g was used in all further examinations in order to 
be as close as possible at conditions of immune-mediated liver diseases. 
Nevertheless, findings indicate that hepatic damage by ConA and the role of IL-6 
within this model was dose and time dependent. 
Administration of a lower dose of ConA (12.5 µg/g) also led to significant but not 
lethal hepatitis, as demonstrated by a profound occurrence of serum ALT 8 h and 
24 h post-ConA injection compared to untreated mice (Fig. 6), which at 48 h 
almost returned to base-line levels. However, an unexpected distinctive reduction 
in serum ALT levels 8 h after ConA administration in IL-6 deficient mice was 
observed (Fig. 6A). Histological examination of the liver by H&E staining of fixed 
liver sections showed large areas of necrotic liver damage 48 h after ConA 
administration in wild-type mice, whereas IL-6 deficient mice showed less and 
smaller areas of damage (Fig. 6D). To verify the data found in experiments with 
IL-6 deficient mice, a single injection of neutralizing anti-IL-6 antibody was applied 
to wild-type mice 16 h before ConA administration. Inhibition of IL-6 signaling 
resulted in reduced liver damage as shown by reduced ALT levels compared to 
control animals (Fig. 6B). Histological examination of the liver displayed markedly 
less and smaller areas of liver damage 48 h after Con-A administration (Fig. 6E). 
Taken together, these findings indicate that independent of ConA-dosage 
endogenous IL-6 contributes to liver damage during the first hours of ConA-
mediated hepatitis progression and also influences the degree of severity. To 
further elucidate how IL-6 signaling contributes to the onset of ConA-mediated 
hepatits downstream activation of STAT3, induction of immune-response related 
cytokines and activation of immune cells was examined. 
IL-6 activation of STAT3 in hepatocytes plays an important role in protection 
against liver injury induced by various toxins (58,92,111). Western blot analysis 
and histochemical analysis demonstrate that attenuated STAT3 signaling in IL-6 
deficient and anti-IL-6 anitbody treated mice (Fig. 8) correlated with liver damage 
(Fig. 6), suggesting that reduced IL-6/STAT3 signaling protected against liver 
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damage in ConA-mediated hepatitis. IL-6 is the major cytokine responsible for 
STAT3 activation in liver regeneration (58) and CCl4-induced liver injury (117), 
since such activation is not detecable in IL-6 deficient mice under these conditions. 
However, STAT3 activation was reduced but not abolished in IL-6 deficient and 
anti-IL-6 antibody treated mice (Fig. 8), suggesting that other cytokines than IL-6 
are also involved in STAT3 activation during ConA-induced hepatitis. Indeed, IFN-
γ may partially contribute to STAT3 activation in this model, since injection of IFN-
γ has been shown to induced significant activation of STAT3 in the liver of mice 
(92). 
The molecular and cellular mechanisms underlying ConA-induced hepatitis have 
been extensively investigated, but are still not fully understood. No cellular 
receptor for ConA molecules has been defined yet and mutiple cells and cytokines 
have been implicated in ConA-mediated hepatitis, suggesting that T-cell mediated 
hepatitis results from complex interactions of multiple cell types and cytokines. 
Although CD4+ T-cells are key players in this model, several cell depletion studies 
showed that other cell types including NKT cells, Kupffer cells and neutrophils are 
also required to induce an intense ConA-mediated hepatitis (39). The major role of 
CD4+ effector T-cells has been well described, e.g. mice pretreated with a T-cell 
specific immunosuppressive drug failed to develop massive cellular recruitment 
and hepatic inflammation in response to ConA (85). In addition, studies with 
heparin treatment before ConA challenge indicated that it was neither the 
agglutination capacity nor the sugar specificity per se that determined the in vivo 
hepatoxic potential of the lectin ConA (116). It appeared that ConA substituted for 
the signal provided by macrophages through peptides bound to MHC class II 
molecules. Indeed, it was shown that ConA bound to the MHC of target cells 
(118). The involvement of macrophages in ConA hepatitis was not only shown by 
the absence of ConA-inducible lesions in macrophage-depleted animals but also 
by the morphological demonstration of macrophage-lymphocyte interactions. 
Thus, this experimental disease is probably produced by both lymphocytes and 
macrophages. The protection by anti-CD4 antibodies against ConA suggested a 
mechanism in which CD4+-bearing THelper(TH)-cells recognized the ConA-modified 
MHC structures of macrophages and became activated. Such a mechanism, i.e. 
TH-cell activation followed by inflammatory tissue destruction, was also told to be 
responsible for the autoimmune disease rheumatoid arthritis (119). The finding 
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that the liver is the target organ of ConA-induced toxicity in vivo may be due to the 
fact that this organ contains the majority of macrophages in the body, named 
Kupffer cells. After intravenous injection of ConA, this resident macrophage 
population exposed to the circulation is primarily reached by the lectin. Therefore, 
it also seems likely that T-cell activation first starts within the liver and thus 
explains the distinct organotropy of ConA in terms of toxicokinetics.  
Besides NKT cells and macrophages the liver contains a large resident and 
migratory population of leukocytes that provide immunosurveillance against 
foreign antigens. This hepatic population can be rapidly expanded in response to 
infection or injury by recruiting leukocytes from circulation. Moreover, acute and 
chronic hepatitis is pathologically characterized by a prominent infiltration of 
lymphocytes to the liver (120). Neutrophils, the numbers of which increase 
significantly after ConA administration, are also involved in the initiation and 
propagation of ConA-induced hepatitis. It has been demonstrated that neutrophil 
depletion reduced CD4+ T-lymphocyte infiltration and completely prevented the 
development of hepatitis, suggesting a major role for neutrophils in the 
pathogenesis of ConA-mediated hepatitis (87,107). Besides their role in 
lymphocyte attraction, neutrophils themselves can act as effector cells and cause 
apoptosis and necrotic tissue destruction by massive secretion of proteases or 
reactive oxygen species (121-123). Indeed, pathology analysis by 
immunohistochemistry in the livers of ConA-treated mice showed neutrophil 
infiltration in pericentral and periportal areas with spotty, focal and submassive 
necrosis (Fig. 10A & 12A). Quantification of these neutrophils revealed 
significantly reduced numbers of infiltrated neutrophils in the livers of IL-6 deficient 
mice and mice treated with anti-IL-6 antibody before ConA challenge (Fig. 10B), 
pointing to a correlation of abrogated IL-6 signaling, reduced neutrophil numbers in 
the liver and the reduced liver damage marker ALT. Although neutrophil numbers 
in the liver were reduced in ConA-treated IL-6 deficient mice with abrogated 
classic IL-6 signaling, unchanged levels of the neutrophil attracting chemokine KC 
were observed (Fig. 13B), which indicated that neutrophil recruitment processes 
into the liver were not affected by IL-6 blockade. This hypothesis was underlined 
by investigation of neutrophil levels in the peripheral blood of mice 8 h after ConA 
injection. In the circulation, mice with abrogated IL-6 signaling again revealed 
reduced neutrophil numbers compared to control mice (Fig. 14A) indicating that 
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IL-6 signaling rather contributed to neutrophil release to the circulating system 
than neutrophil recruitment to organs. In previous studies it has been shown that 
IL-6 induced a release of neutrophils from the bone marrow (124). Indeed, 
intravenous injection of recombinant IL-6 to mice resulted in increased neutrophilic 
levels in systemic circulation (Fig. 14B). The main source of IL-6 is thought to be 
Kupffer and hepatic sinusoidal endothelial cells but also liver-associated T-cells 
have been reported to secrete IL-6 upon ConA application (13,125,126). Analysis 
of IL-6 signaling during ConA-mediated hepatitis revealed that IL-6 signaling was 
responsible to mount an efficient neutrophilia which than contributed to destructive 
ConA-effects and presents a mechanism of IL-6 during ConA-mediated hepatitis 
that is not restricted to the liver.  
Furthermore, levels of NKT cells, CD4+ T-cells and activated CD4+ T-cells, which 
were all described to be harmful during ConA-mediated hepatitis were found to be 
diminished in IL-6 deficient mice compared to control animals (Fig. 9A-C). In 
addition, neutrophil depleted mice, which were found to be completely protected 
from ConA-induced liver damage, exhibited no alterations in levels of NKT and 
CD4+ T-cells compared to control animals (Fig. 12). These two findings indicate 
that IL-6 is involved in and necessary for T-cell recruitment to the liver but 
activation of these cells’ harmful potential might be counteracted by interaction 
with neutrophils and therefore presents another, indirect way of IL-6 signaling 
during ConA-mediated hepatitis. 
In addition to cellular responses also immunoregulatory cytokines play a central 
role in the pathogenesis of ConA-mediated hepatitis with studies pointing to a 
proinflammatory role of TNF-α, IFN-γ, IL-12 and IL-4, and a protective role of IL-10 
and MCP-1 (127). MCP-1 levels were found to be reduced in IL-6 deficient mice 
and mice treated with anti-IL-6 antibody 8 h after ConA treatment compared to 
control mice (Fig. 13A). Also neutrophil depleted mice showed reduced serum 
MCP-1 levels compared to control animals 8 h after ConA application. In a Listeria 
monocytogenes infection model, phagocytosis of neutrophils by Kupffer cells has 
been claimed to inhibit MCP-1 expression by Kupffer cells (106). A protective 
effect of MCP-1 in ConA-mediated hepatitis was demonstrated since neutralization 
of MCP-1 led to an increase in liver damage and increased hepatodestructive IL-4 
secretion from activated liver-resident NKT cells (95). Recombinant MCP-1 was 
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able to reduce IL-4 production in vitro by ConA-costimulated NKT cells (95). IL-4 
expression was also found to be reduced in IL-6 deficient and anti-IL6 antibody 
treated mice (Fig. 13C). Therefore, IL-6 may again contribute to hepatocyte 
damage by indirect neutrophil-mediated processes affecting macrophage 
expression of hepatoprotective MCP-1 and subsequently altered IL-4 expression 
in NKT cells. 
 
4.2 IL-6 trans-signaling has no impact during 
hepatodestructive events in ConA-induced hepatitis 
Application of sgp130Fc has been shown to have beneficial effects in animal 
models of inflammation (65), autoimmunity (81) and cancer (82) pointing to the 
importance and abundance of IL-6 trans-signaling in biological processes. In an 
air-pouch model of acute inflammation, transgenic sgp130Fc overexpressing mice 
have been shown to exhibit impaired leukocyte recruitment and reduced levels of 
MCP-1. Infiltrating neutrophils were the main source of soluble IL-6 receptor 
(128,129). Double transgenic mice for IL-6 and the soluble IL-6R had a higher liver 
weight and showed extramedullary hematopoiesis in liver and spleen and 
developed multifocal hepatocellular hyperplasia (74,103). IL-6 levels have been 
shown to be strongly increased during chemical liver damage induced by 
substances such as D-Galactosamine (130). Blockade of IL-6 trans-signaling by 
sgp130Fc showed that liver regeneration and regulation of glycogen consumption 
in the D-Gal liver toxicity model is mediated by IL-6 and the soluble IL-6R. These 
data showed that IL-6 trans-signaling processes in the liver are possible despite 
expression of membrane-bound IL-6R on liver cells including hepatocytes (104).  
Taken together, these findings led to the assumption that IL-6 trans-signaling 
processes may also be of particular importance during ConA-mediated hepatits 
since the role of classic IL-6 signaling was discussed in the previous chapter. 
Therefore, the role of IL-6 trans-signaling was investigated during ConA-mediated 
hepatitis using IL-6 trans-signaling inhibitor sgp130Fc. Interestingly the protection 
observed in IL-6 deficient and anti-IL-6 antibody treated mice was not mediated by 
IL-6 trans-signaling, since mice pretreated with sgp130Fc before ConA challenge 
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showed liver damage comparable to control mice (Fig. 6C&F). Even though liver 
cells including hepatocytes and Kupffer cells express IL-6R and are therefore a 
likely target of classic IL-6 signaling, the liver is also a target of IL-6 trans-
signaling. In this setting an activation of IL-6 trans-signaling enhanced stimulatory 
effects of IL-6 (131). Since hepatocytes express far more gp130 than IL-6R on the 
cell surface, the total number of activated gp130 molecules is higher when IL-6 
plus sIL-6R is present (132). This effect might also been found during ConA 
hepatitis, since sgp130Fc pretreated mice displayed slightly but not significantly 
reduced STAT3 phosphorylation compared to control animals (Fig. 8). However, 
no differences in neutrophil recruitment to the liver and neutrophil release to 
circulation was observed in sgp130Fc mice compared to control mice 
(Fig. 10 & 14). Also, levels of NKT cells and CD4+ T-cells were not altered in IL-6 
trans-signaling blocked animals compared to controls (Fig. 9D-F). These findings 
indicated that IL-6 trans-signaling has only minor influence during the first onset of 
immune-mediated processes in the ConA-mediated hepatitis model. However, one 
result was found to be different in sgp130Fc treated mice compared to control 
animals and IL-6 deficient mice. Serum KC levels were significantly diminished in 
sgp130Fc mice (Fig. 13B), suggesting that IL-6 trans-signaling enhances induction 
of neutrophil attractant proteins by liver cells after ConA-injection. Nevertheless, 
this effect seemed to be without effect in the complex immunological events 
induced by ConA since diminished KC levels had no influence on neutrophil 
infiltration (Fig. 10). 
 
4.3 Dual role of IL-6 
The role of IL-6 in Con-A induced liver injury is confusing with hepatoprotective 
effects when IL-6 is injected before Con-A induced liver injury, but 
hepatodestructive when IL-6 is administered after Con-A injection (90) (114) (133). 
A similar protective effect of pre- but not post-treatment with IL-6 has also been 
reported in mice given a lethal challenge with endotoxin (134). Mice pretreated by 
intravenous injection of recombinant IL-6 were completely protected from ConA-
induced liver damage (Fig. 15A). IL-6 serum levels were found to be elevated in 
IL-6 pretreated and control mice (Fig. 15D) indicating that IL-6 pretreatment had 
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no effect on IL-6 release after ConA injection. Levels of liver infiltrating neutrophils 
and circulating neutrophils were also equally elevated in IL-6 protected mice and 
control animals with severe liver damage (Fig. 15E&F). However, a second line of 
neutrophils, released from the bone marrow after first release stimulus by 
recombinant IL-6, has been shown to exhibit altered properties with high levels of 
F-actin and less deformability (124). In addition, MCP-1 and KC serum levels in 
IL-6 protected mice after ConA challenge were reduced compared to not protected 
mice (Fig. 15B&C). Therefore, the following mechanism is likely. IL-6 pretreatment 
induced release of neutrophils from the bone marrow. These neutrophils infiltrated 
the liver without doing any harm to hepatocytes since no antigenic ConA was 
attached to liver cell surfaces. After ConA was injected, a second wave of 
neutrophils was released to the circulation with reduced potential to induce liver 
damage due to altered harmful properties. Primary neutrophils were already taken 
up and digested from macrophages, indicated by reduced MCP-1 levels in IL-6 
pretreated mice. Consequently, no harm was done to hepatocytes by getting in 
contact with ConA. A protective effect of IL-6 treatment before ConA challenge 
might thus be due to pre-release and clearance of neutrophils with effector 
potential or high protease/reactive oxygen species load and release of immature 
neutrophils without harmful properties subsequent to ConA challenge.  
Induction of anti-apoptotic protein expression in hepatocytes was presumed to be 
another mechanism contributing to IL-6/STAT3-mediated protection against ConA-
induced hepatitis, since it has been implicated in protection against hepatocyte 
death induced by a variety of hepatoxins, including CCl4 (117), Fas ligand (111) 
and alcohol (92). However, the protective effects of IL-6/STAT3 were unlikely to be 
mediated by induction of anti-apoptotic bcl-2 and FLIP protein expression in 
hepatocytes because similar activation was observed in mice pretreated with 
recombinant IL-6 and in control mice (Fig. 15G) suggesting that protection by IL-6 
in ConA-mediated hepatitis is rather due to reduced induction of proapoptic 
cytokines like TNF-α than activation of anti-apoptotic genes. 
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4.4 Essential role of IL-6 signaling in tolerance 
development towards ConA-induced hepatitis 
The liver is a major presentation site of antigens causing T-cell inactivation, 
tolerance induction and apoptosis, likely due to the need of maintaining 
immunological tolerance towards gut-derived food antigens (135). The overall 
predisposition of intrahepatic T-cell responses toward tolerance might account for 
survival of liver allografts without immuno-supression and persistance of liver 
pathogens, i.e. hepatitis B or C virus (136). In previous studies, the tolerogenic 
mechanisms of the liver have been examined predominantly with a focus on 
T-cells (137). A single injection of a sublethal dose of ConA to mice induced 
tolerance toward ConA-induced liver damage within 8 days pointing to 
suppression of TH1 responses and increased IL-10 production being crucial for the 
tolerogenic state (112). Furthermore, IL-6 levels have been shown to be at 
baseline levels after a retreatment with ConA, suggesting that IL-6 had no 
influence in tolerance-mediating processes. Indeed, IL-6 levels were found not 
elevated after a second challenge with ConA (Fig. 16B). In addition, IL-6 deficient 
mice and control mice revealed baseline ALT levels 8 h after ConA rechallenge. 
Suprisingly, 24 h after ConA rechallenge, IL-6 deficient mice were found to 
develop severe liver damage defined by increased ALT levels and massive 
necrosis in H&E stained liver sections (Fig. 16A&C). Besides, severe liver necrotic 
areas were found accompanied by strong accumulation of neutrophils 
(Fig. 16C&D), suggesting that this time IL-6 independent mechanisms are 
responsible for efficient neutrophil release from the bone marrow. Furthermore, 
levels of CD4+ T-cells and NKT cells were found slightly but not significantly 
reduced in affected IL-6 deficient mice compared to control mice (Fig. 16 F&G), 
pointing to a minor role of IL-6 signaling in T-cell recruitment processes during 
ConA rechallenge. In contrast, activation of CD4+ T-cells was markedly increased 
in IL-6 deficient mice compared to control animals (Fig. 16E) pointing to a key 
function of IL-6 mediated T-cell activation during ConA induced hepatitis. 
Coherently, it has been demonstrated that co-cultures of CD4+CD25+ regulatory T-
cells (Treg) and CD4+CD25- responder cells revealed Treg from ConA-tolerant mice 
being more effective in supressing polyclonal T-cell responses than Treg from 
control mice. Moreover, cellular immune therapy with CD4+CD25+ cells prevented 
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ConA-induced liver injury, with higher protection by Treg from ConA-tolerized mice 
(112). Taken together, these findings indicated that Treg response and activation is 
paramount to tolerance development towards immune mediated liver damage and 
IL-6 has an important role in regulatory T-cell development and subsequent 
protection. 
 
4.5 Outlook 
In this work the impact of IL-6 classic- and IL-6 trans-signaling during ConA 
immune-mediated hepatitis was investigated. It was found that classic IL-6 
signaling strongly contributes to the onset of liver damage during the initial phases 
of ConA immune-mediated liver injury and inflammation, whereas inhibition of IL-6 
trans-signaling was found to be not relevant in this process. However, IL-6 was 
found to have paradoxical effects within this model, since IL-6 pretreated mice 
were protected from liver damage likely due to altered neutrophil characteristics 
when released by endogenous IL-6 after ConA challenge. In addition to classic 
homeostatic granulocyte production mediated by G-CSF and GM-CSF, an 
independent pathway stimulated by IL-6 trans-signaling has been shown to 
contribute to emergency granulopoiesis (138). In future experiments, it will 
therefore be interesting to analyze whether inhibition of IL-6 trans-signaling by 
sgp130Fc might have an impact in the observed neutrophilia after IL-6 
pretreatment. Furthermore, diseases mimicked by ConA hepatitis such as 
autoimmune and viral hepatitis are long-term diseases. It would therefore be of 
interest to investigate the impact of permanently high sgp130Fc serum levels on 
the onset and perpetuation of these hepatic disorders, since in mice these 
diseases usually develop over a longer time period and would require the long-
term administration of exogenous sgp130Fc protein. Therefore, continous 
inhibition of IL-6-trans-signaling in sgp130Fc transgenic animals will help to clarify 
the role of sIL-6R-mediated signaling in the bi-phasic release of neutrophils and 
altered characteristics of neutrophils, contributing to development of immune-
mediated liver damage. Future experiments with regulatory T-cells in IL-6 deficient 
and transgenic sgp130Fc overexpressing mice will additionally yield more 
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information about IL-6 signaling pathways in tolerance induction observed in 
ConA- and viral-induced hepatitis.  
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5 Summary 
Interleukin-6 (IL-6) is a pleiotropic cytokine with various cellular functions including 
induction of acute phase proteins in the liver, stimulation of lymphocytes and 
control of regenerative processes including wound healing and liver regeneration. 
Prominent infiltration of lymphocytes into the liver is a hallmark for acute and 
chronic hepatitis. Liver injury induced by intravenous injection of the mitogenic 
plant lectin Concanavalin A (ConA) is considered as a murine model of T-cell 
mediated hepatitis accompanied by up-regulation of proinflammatory cytokines, 
occurrence of CD4+ T-cells in hepatic lesions but also by the involvement of an 
activation of resident hepatic NKT, Kupffer cells and neutrophils.  
In this study, the role of classic IL-6 signaling and IL-6 trans-signaling during 
ConA-mediated hepatitis was investigated using IL-6 deficient mice and mice 
either injected with anti-IL6 mAbs or sgp130Fc. Application of ConA induced liver 
injury in mice with massive hepatocyte necrosis and neutrophil infiltration. 
Surprisingly, IL-6 deficient mice and mice treated with an anti-IL-6 mAb but not 
with sgp130Fc showed reduced ConA induced liver injury. This was accompanied 
by a diminished increase of circulating and liver infiltrating neutrophils, by an 
upregulation of the hepatoprotective C-C chemokine ligand 2 (CCL2)/monocyte 
chemoattractant protein-1 (MCP-1), and by a downregulation of the 
hepatodestructive cytokine IL-4, but by unchanged levels of the neutrophil 
attracting chemokine KC. IL-6 has a dual role in ConA-induced hepatitis, which is 
hepatoprotective when IL-6 is injected before ConA administration and 
hepatodestructive if applicated after ConA administration. A single IL-6 injection to 
mice resulted in release of neutrophils to the circulation. These findings showed 
that abrogated classic IL-6-signaling in ConA mediated hepatitis exhibited liver-
protective effects, which were at least in part caused by the failure to mount an 
efficient neutrophilia. 8 days after a first ConA injection, mice became tolerant 
against ConA restimulation. 24 h after a second ConA-challenge IL-6 deficient 
mice developed severe liver damage accompanied by increased CD4+ T-cell 
activation compared to completely protected wild-type animals. These data 
confirmed a dual mode of IL-6 action during ConA-induced hepatitis pointing to 
early harmful effects mediated by extensive neutrophilia and long term protective 
effects by an altered T-cell activation pattern. 
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6 Zusammenfassung 
Interleukin-6 (IL-6) ist ein pleiotropes Cytokin mit verschiedenen zellulären Funktionen 
wie der Induktion von Akut-Phase Proteinen in der Leber, Stimulation von 
Lymphozyten und ist außerdem bei der Regulierung regenerativer Prozesse wie der 
Wundheilung und Leberregeneration beteiligt. Vermehrte Lymphozyteneinwanderung 
in die Leber ist ein Kennzeichen akuter und chronischer Hepatitis. Intravenöse 
Injektion des Pflanzenlektins Concanavalin A (ConA) führt zu erhöhter Ausschüttung 
proinflammatorischer Cytokine, vermehrtem Auftreten von CD4+ T-Zellen in 
entstehenden Leberlesionen, Aktivierung von NKT Zellen, Kupffer Zellen, 
neutrophilen Granulozyten und gilt als Mausmodell einer T-Zell vermittelten Hepatitis.  
In dieser Arbeit wurde unter Verwendung IL-6 defizienter Mäuse, anti-IL-6 Antikörper 
injizierter Mäuse und sgp130Fc injizierter Mäuse die Rolle von klassischem IL-6 
signaling und IL-6 trans-signaling in der ConA vermittelten Hepatitis untersucht. Die 
Applikation von ConA führte zu einer Schädigung der Leber mit massiver Nekrose 
und Einwanderung von Neutrophilen. IL-6 defiziente und mit anti-IL-6 Antikörpern 
behandelte Mäuse wiesen im Gegensatz zu sgp130Fc behandelten Tieren reduzierte 
Leberschädigung auf. Zudem wurde ein verminderter Anstieg von Neutrophilen im 
Blutkreislauf und der Leber, eine Hochregulierung des hepatoprotektiven monocyte 
chemoattractant protein-1 (MCP-1), eine Herunterregulierung des leberschädigenden 
Cytokins IL-4, aber keine Veränderung des Neutrophilen anziehenden Chemokins KC 
gefunden. IL-6 spielt eine duale Rolle während der ConA vermittelten Hepatitis. IL-6 
Injektion vor ConA Applikation schützt die Leber, während eine IL-6 Injektion nach 
ConA Applikation die Leber schädigt. Eine IL-6 Injektion führte zudem zu einer 
erhöhten Neutrophilenzahl im Blutkreislauf. Die Ergebnisse zeigten, dass 
unterbrochenes klassisches IL-6 signaling während ConA immunvermittelter Hepatitis 
leberschützende Effekte aufwies, die zumindest teilweise auf eine Störung der 
effizienten Freisetzung von Neutrophilen in den Kreislauf zurückzuführen ist. Mäuse 
bilden 8 Tage nach einer ersten ConA Injektion Toleranz gegenüber einer erneuten 
Stimulierung mit ConA aus. Im Vergleich zu geschützten wildtyp Mäusen entwickelten 
IL-6 defiziente erneut einen massiven Leberschaden der 24 Stunden nach ConA- 
Restimulation durch erhöhte Aktivierung von CD4+ T-Zellen gekennzeichnet war. 
Diese Resultate zeigen die duale Wirkungsweise von IL-6 während ConA induzierter 
Hepatitis mit anfänglich schädigenden und langfristig schützenden Effekten. 
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8 Appendix 
8.1 Abbrevations 
Ab Antibody 
ADAM A disintegrin and metalloproteinase 
AIH Autoimmune hepatitis 
ALT Alanine aminotransferase 
ANA Antinuclear antibody 
APC Allophycocyanin 
APS Ammonium peroxodisulfate 
AST Aspartate aminotransferase 
BCA Bicinchoninic acid 
B-cell Bone marrow derived lymphocyte-cell 
Bcl-2 B-cell lymphoma-2 
Bcl-XL B-cell lymphoma-extra large 
BSA Bovine serum albumine 
BSF-3 B-cell stimulatory factor 3 
CCL2 Chemokine (C-C motif) ligand-2 
CCl4 Carbontetrachloride 
CD Cluster of differentiation 
CINC-1 Cytokine-induced neutrophil chemoattractant-1 
CLC Cardiotrophin-like cytokine 
CNTF Ciliary neurotrophic factor 
ConA Concanavalin A 
CRP C-reactive protein 
CSF Colony stimulating factor 
CT-1 Cardiotrophin-1 
CXCL1 Chemokine (C-X-C motif) ligand-1 
Cy7 Cyanine dye 7 
d Days 
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DCs Dendritic cells 
DMSO Dimethylsulfoxide 
EAE Experimental autoimmune encephalomyelitis 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme linked immunosorbent assay 
ERK Extracellular signal regulated kinase 
EtOH Ethanol 
FACS Fluorescence activated cell sorter 
FCS Fetal calf serum 
Fig Figure 
FITC Fluorescein isothiocyanate 
FLIP FLICE-inhibitory protein 
FSC Forward scatter 
g g-force 
G-CSF Granulocyte-colony stimulating factor 
GM-CSF Granulocyte/macrophage -colony stimulating factor 
gp130 Glycoprotein 130 
h Hours 
H&E Hematoxylin & eosin 
HIL-6 Hyper-IL-6 
HLA Human leukocyte antigen 
HRP Horseradish peroxidase 
i.p.-injection Intraperitoneal-injection 
i.v.-injection Intravenous-injection 
ICAM Intercellular adhesion molecule 
IFN Interferon 
IgG Immunoglobulin G 
IL Interleukin 
IL-6R IL-6 receptor 
IVC Individually ventilated cages 
JAK Janus kinase 
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KC Keratinocyte chemoattractant 
kD Kilodalton 
L liter 
LIF Leukemia inhibitory factor 
LKM Liver/kidney microsomal antibody 
LPS Lipopolysaccharide 
Ly6 Lymphocyte antigen 6 
µg microgram 
µl microliter 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
mg milligramm 
MHC Major histocompatibility complex 
min Minutes 
MIP-2 Macrophage-inflammatory protein-2 
ml milliliter 
mM millimolar 
MNC Mononuclear cells 
MOG Myelin oligodendrocyte glycoprotein 
NADPH Nicotinamide adenine dinucleotide phosphate hydrogen 
ng nanogramm 
NK Natural killer 
NKT Natural killer T-cell 
nm nanometer 
NNT-1 New neurotrophin-1 
NP Neuropoietin 
NPN New neuropoietin 
OSM Oncostatin M 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
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PBS-T PBS-Tween 
PE Phycoerythrin 
PMN Polymorphonuclear 
POD peroxidase 
pSTAT3 Phospho-STAT3 
PVDF Polyvinylidene fluoride 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
SAA Serum amyloid A 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
sgp130 Soluble gp130 
sIL-6R Soluble IL-6R 
SMA Anti-smooth muscle actin antibody 
SSC Side scatter 
STAT Signal transducers and activators of transcription 
TACE Tumor necrosis factor-α converting enzyme 
TBS Tris buffered saline 
TBS-T TBS-Tween 
T-cell Thymus derived lymphocytic-cell 
TEMED N,N,N’,N’-Tetramethylethylenediamine 
Th-cell T-helper cell 
TNF Tumor necrosis factor 
TNFR TNF receptor 
Treg Regulartory T-cell 
U Units 
V Volt 
v/v Volume per Volume 
VCAM Vascular adhesion molecule 
w/v Weight per Volume 
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